Introduction {#s1}
============

The histone methyltransferase Su(var)3--9 was first identified in forward genetic screens as a suppressor of position effect variegation in *Drosophila melanogaster* ([@bib81]). Previous studies identified important functions for the evolutionarily conserved SUV39 proteins in the silencing of heterochromatin, as well as in chromosome segregation and cell division ([@bib23]; [@bib55]; [@bib64]). This family of chromatin-modifying enzymes includes Clr4 in fission yeast ([@bib60]), as well as SUV39H1 and SUV39H2 in humans ([@bib71]). SUV39 proteins catalyze the di- and tri-methylation of lysine 9 of histone H3 (H3K9me2/3), and these histone modifications are bound by chromodomain-containing proteins, including the SUV39 enzymes themselves and the HP1 family of proteins ([@bib3]; [@bib7]; [@bib48]; [@bib59]; [@bib85]). HP1 protein binding to H3K9me2/3 chromatin is then thought to drive chromatin compaction and transcriptional repression through oligomerization ([@bib14]; [@bib24]; [@bib33]).

SUV39H1 and H3K9me3 are predominately associated with constitutive heterochromatin, which represses 'selfish' genetic elements and repetitive DNA to promote genomic stability ([@bib12]; [@bib64]). In many eukaryotes, constitutive heterochromatin is concentrated at the repetitive sequences flanking centromeres, and is termed pericentric heterochromatin. In fission yeast, disruption of pericentric heterochromatin causes chromosome cohesion defects and chromosome missegregation ([@bib9]); and in mammals, defective pericentric heterochromatin and aberrant transcription of pericentric repeats are associated with genomic instability and cancer ([@bib64]; [@bib80]; [@bib92]). These defects in constitutive heterochromatin are most evident in SUV39H1 and SUV39H2 double knockout mice, which exhibit reduced embryonic viability, small stature, chromosome instability, an increased risk of tumor formation, and male infertility owing to defective spermatogenesis ([@bib64]). Human SUV39H1 has been implicated in a variety of complex biological processes such as DNA damage repair ([@bib4]; [@bib6]; [@bib90]), telomere maintenance ([@bib29]; [@bib67]), cell differentiation ([@bib5]; [@bib76]), and aging ([@bib88]).

Despite the fundamental role of SUV39H1 and SUV39H2 in heterochromatin formation, it is largely unclear how these enzymes are localized at specific genomic sites to generate heterochromatin. Other chromatin modifiers -- in addition to binding DNA, post-translationally modified histones, and other chromatin-associated proteins -- depend on interactions with noncoding RNAs for their proper localization ([@bib54]; [@bib72]). In fission yeast, the localization of pericentric heterochromatin proteins, including the SUV39 homolog Clr4, relies on the RNAi machinery ([@bib13]; [@bib33]; [@bib56]), and RNAi has also been implicated in heterochromatin formation in other eukaryotic systems as well ([@bib26]; [@bib63]). Recent studies reported that RNA is involved in targeting SUV39H1 to telomeres and to the *Oct4* locus ([@bib67]; [@bib76]); however, it is unclear whether RNA plays a broader role in SUV39H1-dependent heterochromatin formation, and if direct RNA binding regulates the association of SUV39H1 with pericentric heterochromatin.

In this study, we establish that chromatin-associated RNA contributes to the localization of SUV39H1 at constitutive heterochromatin in humans. We find that RNA associates with the pericentric heterochromatin of human mitotic chromosomes in primary and immortalized cell lines, and that a portion of this RNA is encoded by pericentric α-satellite sequences. We show that SUV39H1 binds without any observed sequence preference to both DNA and RNA in vitro, and that SUV39H1 binds RNA transcribed from pericentromeric repeats in human cells. Mutations that disrupt the nucleic acid binding function of SUV39H1 cause defects in its localization to pericentric heterochromatin, destabilize SUV39H1's association with chromatin, and result in heterochromatin silencing defects. We propose a model in which the direct binding of SUV39H1 to RNA and to methylated histones ensures proper constitutive heterochromatin function in humans.

Results {#s2}
=======

RNA associates with the pericentric regions of human mitotic chromosomes {#s2-1}
------------------------------------------------------------------------

Chromatin-associated RNA has a well-studied role in the formation of pericentric heterochromatin in fission yeast ([@bib13]; [@bib33]; [@bib56]), but the role of RNA at human pericentric heterochromatin remains largely unexplored. To test if RNA is associated with pericentric heterochromatin in human cells, we used fluorescent pulse labeling of RNA to observe its localization on mitotic chromosomes. Because transcription is largely repressed in mitosis ([@bib30]), RNAs bound to mitotic chromosomes may be more likely to play regulatory roles than RNAs associated with chromatin during interphase. The morphology of condensed mitotic chromosomes also provides landmarks such as the primary centromere constriction and the telomere to facilitate the localization of RNAs.

We visualized chromosome-associated RNA by treating HeLa cells with the modified nucleoside ethynyl uridine (EU) ([@bib41]), centrifuging mitotic chromosomes onto coverslips, and fluorescently labeling the RNA by coupling an azido-modified fluorophore to the alkyne group using copper-catalyzed cycloaddition (click chemistry). The EU-RNA signal we detected on human mitotic chromosomes, although distributed in distinct puncta along chromosome arms, was particularly concentrated around centromeres ([Figure 1A](#fig1){ref-type="fig"}). The RNA signal was sensitive to treatment with Ribonuclease (RNase) A, confirming that our EU treatment specifically labeled RNA; but not sensitive to RNase III or RNase H, indicating that this RNA possesses single-stranded (ssRNA) regions but not nuclease-accessible double-stranded RNA (dsRNA) or RNA-DNA hybrids ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Four out of eight different cell lines showed RNA enrichment at pericentric regions ([Figure 1---figure supplement 1B, C and D](#fig1s1){ref-type="fig"}). Both primary fibroblasts and HeLa cells exhibited pericentric RNA localization, indicating that this phenomenon is not specific to immortalized cells ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}).10.7554/eLife.25299.003Figure 1.RNA associates with the pericentric regions of human mitotic chromosomes.(**A**) RNA localization on human mitotic chromosomes. A schematic of the chromosome-associated RNA labeling approach is shown at top. Mitotic HeLa cells were spun onto coverslips and stained for DNA (blue), ethynyl uridine labeled RNA (EU-RNA, green), and H3K9me3 (red) or CENP-T (red) to mark centromeres. Top row of images: cells were not treated with EU (-EU). Bottom row of images: cells were labeled with EU for 12 hr (+EU). (**B**) α-satellite RNA localization on mitotic chromosomes. Mitotic DLD-1 cells were spun onto coverslips, then α-satellite RNA was detected with a probe recognizing the pericentric D1Z5 array on human chromosome 1 (green). Chromosomes were also stained for DNA (blue), H3K9me3 (red), and HEC1 (red) antibodies to mark pericentric heterochromatin and the core centromere/kinetochore region. (**C**) D1Z5 α-satellite RNA overlaps with pericentric heterochromatin, but not the core centromere/kinetochore. α-satellite RNA FISH with the D1Z5 probe (green) on a stretched DLD-1 mitotic chromosome, co-stained for DNA (blue), H3K9me3 (red), and HEC1 (red). Line scans show α-satellite RNA overlaps with H3K9me3, but not HEC1. (**D**) RNase sensitivity of D1Z5 α-satellite RNA FISH signal. Spread mitotic DLD-1 cells were treated ± RNases, then stained for DNA (blue), D1Z5 α-satellite RNA (green), and H3K9me3 (red). See also [Figure 1---figure supplement 1 and 2](#fig1s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.003](10.7554/eLife.25299.003)10.7554/eLife.25299.004Figure 1---figure supplement 1.Characterization of chromosome-associated pericentric RNA.(**A**) RNase sensitivity of pericentric RNA. EU-labeled mitotic HeLa cells were spun onto coverslips and incubated with or without RNase A, RNase H, or RNase III as indicated, then stained for DNA (blue), EU-RNA (green) and CENP-A (red) to mark centromeres. (**B, C**) Representative images of different types of human cell lines, showing RNA localization on mitotic chromosomes. Cells were labeled with EU for 12 hr, then mitotic cells were spun onto coverslips and stained for DNA (blue), EU-RNA (green), and H3K9me3 (red). (**B**) shows cell lines tested that, like HeLa cells, show RNA concentrated around centromeres. (**C**) shows cell lines tested that show no apparent concentration of RNA around centromeres. (**D**) EU-RNA staining on DLD-1 chromosomes. Cells were labeled with EU and stained as described above. Although α-satellite RNA is detected on DLD-1 chromosomes by RNA FISH, there is little detectable EU-RNA signal. (**E**) β-satellite and Satellite III DNA and RNA on human mitotic chromosomes. Mitotic DLD-1 cells were spread onto coverslips, RNA or DNA FISH was performed to detect Satellite III (green) and β-satellite (red) sequences, and then chromosomes were stained for DNA (blue). The β-satellite probe recognizes sequences on chromosomes 13, 14, 15, 21, and 22, and the Satellite III probe recognizes sequences on chromosomes 14 and 22. (**F**) RNA FISH for D1Z5, a chromosome 1 specific α-satellite array, on HeLa mitotic chromosomes. Mitotic HeLa cells were spread onto coverslips, RNA FISH was performed to detect chromosome 1-specific D1Z5 α-satellite sequences (green), and chromosomes were stained for HEC1 to mark centromeres (red) and with Hoechst to stain for DNA (blue). (**G**) RNA FISH on DLD-1 chromosomes with a probe specific to an α-satellite array on chromosomes 13 and 21. Mitotic DLD-1 cells were spread onto coverslips, RNA FISH was performed to detect α-satellite 13/21 (green), and then chromosomes were stained for DNA (blue) and H3K9me3 (red). Line scans of all four 13 and 21 chromosomes show localization of α-satellite RNA and H3K9me3. White arrows delineate direction of line scan, and the labeling of homologous chromosomes as 'homolog 1' or 'homolog 2' is arbitrary. The Y-axis represents the pixel intensity along the drawn line.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.004](10.7554/eLife.25299.004)10.7554/eLife.25299.005Figure 1---figure supplement 2.Identifying the transcriptional requirements for chromosome-associated RNA.(**A**) Representative images showing chromosome-associated EU-RNA signal after inhibiting RNA polymerases. HeLa cells were incubated with 0.5 mM EU and 50 μg/mL α-amanitin, 1 μM triptolide, 50 ng/mL actinomycin D, or 1 μM CX-5461 for 6 hr, then mitotic cells were spun onto coverslips and stained for DNA (blue), EU-RNA (green), and HEC1 to mark centromeres (red). (**B**) Quantificaton of EU-RNA at pericentric regions and RT-qPCR controls to assess inhibition of transcription by different RNA polymerase inhibitors. Far left panel: images from the experiment shown in **A** were quantified using pericentromere finder software and HEC1 staining as a centromere marker. Shown are the means of 3 separate experiments, 15 images quantified per condition per experiment. Four rightmost panels: total RNA was purified from cells treated with the indicated polymerase inhibitors (same cells shown in **A**), and RT-qPCR was performed with primers for control RNAs to check for inhibition of specific polymerases and to measure α-satellite RNA levels. All values were normalized to GAPDH RNA levels. Shown are the means of 3 separate experiments. All error bars represent standard error. (**C**) Diagram describing EU pulse/chase experiment to assess when chromosome-associated RNA is being transcribed. HeLa cells were incubated with 2 mM thymidine for 19 hr, then thymidine was washed out and 0.5 mM EU was added at the indicated time intervals before mitotic shake off. (**D**) Resulting mitotic spreads from experiment outlined in **C**, showing that chromosome-associated RNA is transcribed in the few hours before mitosis. Cells were harvested by mitotic shake off, spun onto coverslips, and stained for DNA (blue), and EU-RNA (green).**DOI:** [http://dx.doi.org/10.7554/eLife.25299.005](10.7554/eLife.25299.005)

Characterization of pericentric RNA {#s2-2}
-----------------------------------

A previous study demonstrated that transcription by RNA polymerase II (Pol II) can occur from the core centromere regions of human mitotic chromosomes ([@bib16]). This RNA is presumably transcribed directly from the underlying centromeric DNA sequences, which in humans are composed of α-satellite repeats. α-satellite sequences, as well as other repeat classes -- such as β-satellite and Satellite III -- are also present at human pericentric regions ([@bib19]; [@bib31]). To determine which RNA sequences are localized at pericentric heterochromatin, we performed RNA FISH with different repeat-specific probes. We used DLD-1 cells for this analysis, as they have a more stable karyotype than HeLa cells and allow for more reliable chromosome identification. We saw no RNA FISH signal with β-satellite (chromosomes 13, 14, 15, 21, and 22) or Satellite III (chromosomes 14 and 22) probes despite observing clear DNA FISH signal ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). However, we detected RNA FISH signal with two different α-satellite probes, one of which was specific for the pericentric α-satellite array D1Z5 ([Figure 1B and C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}) ([@bib66]). This signal was sensitive to RNase treatment ([Figure 1D](#fig1){ref-type="fig"}) and colocalized with H3K9me3 staining ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}), but not with HEC1 staining that labels the core centromere/kinetochore ([Figure 1C](#fig1){ref-type="fig"}). We also observed that α-satellite RNA was localized in cis (i.e. at the same site of its transcription), as we saw that the RNA FISH signal was constrained to only the chromosomes known to contain the specific α-satellite DNA sequences recognized by our probes ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1F and G](#fig1s1){ref-type="fig"}). Interestingly, even though we detected EU-RNA signal enriched at pericentric regions on HeLa chromosomes and not on DLD-1 chromosomes ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B and D](#fig1s1){ref-type="fig"}), we detected α-satellite RNA by RNA FISH in both cell types ([Figure 1C and D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}), indicating that α-satellite RNA is localized at pericentric regions even in cells lines with low pericentric EU-RNA signal.

To determine which RNA polymerase transcribes the pericentric RNA, we added different polymerase inhibitors to cells during EU treatment. We measured a reduction of approximately 50% in pericentric RNA signal after treatment with α-amanitin or triptolide -- which preferentially inhibit Pol II -- but observed a complete loss of signal after treatment with actinomycin D or CX-5461 -- which preferentially inhibit Pol I, and show no detectable Pol II inhibition ([Figure 1---figure supplement 2A and B](#fig1s2){ref-type="fig"}). Thus, most of the pericentric RNA signal we observe appears to be transcribed by Pol I. Total α-satellite RNA levels were not decreased by any RNA polymerase inhibition, suggesting that the amount of α-satellite transcribed in our 6 hr treatment window is likely a small percentage of the total α-satellite RNA ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}).

Our data does not exclude the possibility that some Pol II-dependent transcription is also occurring at the core centromere, as has been previously reported in human cells ([@bib16]). In that study, incorporation of fluorescent nucleotides was only assayed on mitotic chromosomes, and because we label cells with EU for a longer time period (4--12 hr), we are likely observing a broader set of RNAs that are being transcribed before and during mitosis.

To investigate the cell cycle timing of pericentric RNA synthesis, we either labeled cells continuously prior to mitosis, or for a short pulse followed by washout prior to mitosis. We found that continuous EU labeling for 8 or 4 hr before mitosis led to pericentric EU-RNA signal, but a 4 hr EU pulse followed by a 4 hr chase resulted in no EU-RNA signal on mitotic chromosomes ([Figure 1---figure supplement 2C and D](#fig1s2){ref-type="fig"}). This suggests that the pericentric RNA we observe on mitotic chromosomes is transcribed within the 4 hr before mitosis, or that it is transcribed earlier but dissociates from chromosomes in the 4 hr washout period after labeling.

SUV39H1 localization depends on chromatin-associated RNA {#s2-3}
--------------------------------------------------------

The finding that RNA is bound to the pericentric regions of human mitotic chromosomes is intriguing in light of previous observations that direct RNA binding by the heterochromatin factors Polycomb Repressive Complex 2 (PRC2) and HP1α is important for their proper localization and function ([@bib58]; [@bib89]). Because SUV39 enzymes are the primary H3K9 methyltransferases acting at pericentric regions, we tested if the association of SUV39H1 with pericentric heterochromatin also depends on RNA. We digested chromosomes with RNase A and assessed SUV39H1 localization. In a stable HeLa cell line expressing GFP-tagged SUV39H1 under doxycycline inducible control, we induced expression with a 6 hr pulse of doxycycline to avoid SUV39H1 mislocalization to chromosome arms caused by overexpression ([@bib55]). We found that RNase A treatment reduced the pericentric localization of SUV39H1 to 43 ± 4% of the untreated control, and that SUV39H1 localization could be completely rescued by adding specific RNase inhibitors ([Figure 2A and B](#fig2){ref-type="fig"}). DNA staining at pericentric regions was not reduced in this experiment, indicating that the general chromosome structure at pericentric heterochromatin was not disrupted by RNase A treatment ([Figure 2C](#fig2){ref-type="fig"}). We also determined that total SUV39H1 protein levels are not affected by RNase A treatment ([Figure 2---figure supplement 1M](#fig2s1){ref-type="fig"}). These data demonstrate that SUV39H1 depends on the presence of RNA for its localization on human mitotic chromosomes.10.7554/eLife.25299.006Figure 2.SUV39H1 localization on mitotic chromosomes is disrupted by RNase treatment.(**A**) Mitotic HeLa cells expressing or not expressing SUV39H1-GFP (+/-dox) were spread onto coverslips and incubated without RNase, with RNase A, or with RNase A plus RNase inhibitors. Cells were then stained for DNA (blue), anti-GFP to detect SUV39H1 (green), and HEC1 to mark centromeres (red). (**B**) Quantification of SUV39H1-GFP pericentric signal. The graph shows the average signal after subtracting background (-dox) and normalizing to control levels (+dox, -RNase A). n = 5 separate experiments, 15 cells quantified per condition per experiment, error bars are standard error. (**C**) Quantification of DNA pericentric signal. The graph shows the average signal after normalizing to control levels (+dox, -RNase A). n = 5 separate experiments, 15 cells quantified per condition per experiment, error bars are standard error. See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.006](10.7554/eLife.25299.006)10.7554/eLife.25299.007Figure 2---figure supplement 1.Characterization of SUV39 DKO human cells.(**A**) Western blot analysis of HeLa SUV39 DKO cells, assessing total SUV39H1, HP1α, tubulin, and H3K9me3 levels. (**B**) Analysis of SUV39H2 loci in HeLa SUV39 DKO cells. A section of the SUV39H2 gene surrounding the targeted Cas9 cut site was PCRed from genomic DNA and sequenced. Two mutant alleles were identified, and both lead to an early translation termination of SUV39H2. (**C**) α-satellite RNA levels in HeLa SUV39 DKO cells were measured by reverse transcription followed by quantitative PCR (RT-qPCR). Total RNA was isolated from HeLa control and HeLa SUV39 DKO cells, then reverse transcribed and amplified with α-satellite or GAPDH primers. Shown is average of 5 independent measurements, normalized to control cells, error bars are standard error. (**D**) H3K9me3 localization in control or SUV39 DKO HeLa cells. Mitotic cells were spread onto coverslips, then stained for DNA (blue), H3K9me3 (green), and HEC1 (red) to mark core centromere/kinetochore regions. (**E**) HP1α localization in control or SUV39 DKO HeLa cells. Mitotic cells were spread onto coverslips, then stained for DNA (blue), HP1α (green), and HEC1 (red) to mark core centromere/kinetochore regions. (**F**) Analysis of repetitive RNAs in HeLa SUV39 DKO cells. Total RNA was isolated from HeLa control and HeLa SUV39 DKO cells, and a cDNA library was generated and sequenced. Fold change in RNAs (SUV39 DKO / control) transcribed from different repeat types were plotted as a rank order from highest to lowest. Repeat types with over 300 reads were included. The horizontal gray dotted line represents a cutoff of 2 standard deviations from the mean of the dataset. Brown dots represent repeat types that fall under two standard deviations from the mean. Repeats that were enriched more than two standard deviations from the mean are labeled, and colors represent the RepeatMasker broad repeat class to which that repeat type belongs. (**G**) Comparative analysis of non-repetitive RNA levels in HeLa control and HeLa SUV39 DKO cells. RNA was isolated and sequenced as described in **F**, and non-repetitive (uniquely mapping) RNAs were analyzed. FPKM: Fragments Per Kilobase of transcript per Million mapped reads. (**H**) Western blot analysis of DLD-1 SUV39 DKO cells, assessing total SUV39H1, HP1α, tubulin, and H3K9me3 levels. (**I**) Analysis of SUV39H2 loci in DLD-1 SUV39 DKO cells. A section of the SUV39H2 gene surrounding the targeted Cas9 cut site was PCRed from genomic DNA and subjected to MiSeq sequencing. Two mutant alleles were identified, and both lead to an early stop in the translation of SUV39H2. (**J**) α-satellite RNA levels in DLD-1 SUV39 DKO cells were measured by reverse transcription followed by quantitative PCR (RT-qPCR). Total RNA was isolated from DLD-1 control and DLD-1 SUV39 DKO cells, then reverse transcribed and amplified with α-satellite or GAPDH primers. Shown is average of 5 independent measurements, normalized to control cells, error bars are standard error. (**K**) H3K9me3 localization in control or SUV39 DKO DLD-1 cells. Mitotic cells were spread onto coverslips, then stained for DNA (blue), H3K9me3 (green), and HEC1 (red) to mark core centromere/kinetochore regions. (**L**) α-satellite RNA localization in control or SUV39 DKO DLD-1 cells. Mitotic cells were spread onto coverslips, then stained for DNA (blue), α-satellite (D1Z5 probe, green), and HEC1 (red) to mark core centromere/kinetochore regions. (**M**) Western blot showing SUV39H1 and histone H3 protein levels in cell lysates treated with RNase A or RNase A plus RNase inhibitors.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.007](10.7554/eLife.25299.007)

SUV39H1 binds directly to HP1 proteins ([@bib87]), and mouse HP1α protein can directly bind RNA ([@bib58]). Given that SUV39H1, HP1α, and RNA interact with one another, we tested the effect of SUV39 protein loss on HP1α and RNA localization. Using CRISPR/Cas9-mediated gene targeting, we generated SUV39H1 and SUV39H2 double knockout (SUV39 DKO) human HeLa and DLD-1 cell lines ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) that lack expression of both SUV39H1 and the partially redundant SUV39H2 proteins ([Figure 2---figure supplement 1A, B, H and I](#fig2s1){ref-type="fig"}). As observed in SUV39 double null mouse cells ([@bib48]; [@bib64]), both H3K9me3 levels and HP1α localization were substantially reduced in human SUV39 DKO cells ([Figure 2---figure supplement 1A, D, E, H and K](#fig2s1){ref-type="fig"}). However, the levels of centromeric satellite RNA, including α-satellite RNA, increased in SUV39 DKO cells ([Figure 2---figure supplement 1C, F and J](#fig2s1){ref-type="fig"}) ([@bib49]), consistent with SUV39H1/SUV39H2 loss causing defective heterochromatin and transcriptional depression of centromeric satellites. In contrast to the de-repression of satellite RNA, we saw no significant changes in global RNA expression levels ([Figure 2---figure supplement 1G](#fig2s1){ref-type="fig"}). In the absence of SUV39H1 and SUV39H2, α-satellite RNA continued to localize to pericentric heterochromatin as assayed by RNA FISH ([Figure 2---figure supplement 1L](#fig2s1){ref-type="fig"}). Together, our data is consistent with a model in which RNA transcribed from pericentric α-satellite sequences maintains an association with the site of transcription during mitosis. In the absence of the SUV39 enzymes, α-satellite transcripts remain localized at pericentric regions, but transcriptional silencing, HP1α localization, and H3K9me3-dependent heterochromatin are disrupted.

SUV39H1 directly binds nucleic acids through its chromodomain {#s2-4}
-------------------------------------------------------------

To determine whether SUV39H1 can bind RNA directly, we performed electrophoretic mobility shift assays (EMSAs) with a random 19-mer ssRNA oligonucleotide and MBP-tagged human SUV39H1 protein purified from *E. coli*. Because we were unable to purify full-length SUV39H1 protein free of degradation products, we purified truncations of SUV39H1 containing either the N-terminal extension alone (amino acids 1--41), the chromodomain alone (amino acids 42--106), the N-terminal extension plus the chromodomain (amino acids 1--106), or the C-terminus consisting of the pre-SET, SET, and post-SET domains (amino acids 107--412) ([Figure 3A and B](#fig3){ref-type="fig"}). We found that the SUV39H1 truncations containing the chromodomain bound to RNA with the highest affinity, whereas the C-terminal fragment showed no detectable binding ([Figure 3C and D](#fig3){ref-type="fig"}). The addition of the N-terminal extension to the chromodomain of SUV39H1 (1--106) provided a 16-fold increase in affinity relative to the chromodomain alone (42-106), with dissociation constants (K~d~) of 0.15 ± 0.01 µM and 2.31 ± 0.17 µM, respectively. The N-terminal extension alone bound to RNA with a significantly reduced K~d~ (51 ± 30 µM) compared to the truncations containing the chromodomain. Excess unlabeled RNA competed with radiolabeled RNA for binding to SUV39H1 ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), confirming that the RNA gel shift was not due to irreversible aggregation. From these data, we conclude that the chromodomain, SUV39H1 42--106, is sufficient for RNA binding activity. This is consistent with previous findings that chromodomains can act as RNA binding domains ([@bib2]), and that the telomeric TERRA RNA associates with SUV39H1 ([@bib67]).10.7554/eLife.25299.008Figure 3.SUV39H1 directly binds nucleic acids through its chromodomain.(**A**) Domain schematic of SUV39H1 truncations. NTE, N-terminal extension; chromo, chromodomain; pre, pre-SET; post, post-SET. Amino acid residues are listed above and to the left of each truncation. (**B**) Coomassie-stained gel of purified human SUV39H1 truncations fused to MBP. (**C**) Quantification of SUV39H1 domains binding to 19mer RNA. Binding curves are from quantifying EMSAs shown in 3D. Error bars are standard deviation from two independent experiments. Dissociation constants (K~d~, μM) displayed on graph are determined by non-linear fitting of the binding curves. Standard error represents the error of the curve fitting to the average of the two experimental replicates. (**D**) Representative EMSAs showing binding of purified MBP-SUV39H1 truncations with a 19mer RNA oligo (\*), 1--41, 42--106 and 1--106 diluted 2-fold from 100 μM, 107--412 diluted 2-fold from 62 μM. Quantified in **3C**. (**E**) Binding of SUV39H1 to all nucleic acid types. Binding curves are from quantifying EMSAs ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}) of MBP-tagged SUV39H1 1--106 binding to 50mer nucleic acids (ssRNA, ssDNA, dsRNA, dsDNA, or RNA/DNA) ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Various nucleic acids are composed of the first 50 bases of *E. coli* maltose binding protein (MBP): ssRNA1, sense MBP 1--50; ssRNA 2, anti-sense MBP 1--50; ssDNA, sense MBP 1--50. Error bars, dissociation constants (K~d~, μM), and standard error calculated as in **3C**. (**F**) Quantification of MBP-SUV39H1 1--106 binding to 180mer α-satellite or β-actin ssRNA (representative EMSA in [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). Error bars, dissociation constants (K~d~, μM), and standard error calculated as in 3C. See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.008](10.7554/eLife.25299.008)10.7554/eLife.25299.009Figure 3---figure supplement 1.Characterization of SUV39H1-RNA binding in vitro.(**A**) Competitive binding assay measuring the ability of unlabeled 19mer ssRNA to compete with the interaction of labeled 19mer ssRNA binding to MBP-SUV39H1 42--106. MBP-SUV39H1 42--106 present at 12.4 μM, labeled RNA at approximately 3 nM, and unlabeled RNA at concentrations ranging from 30 to 1500 nM. Percent labeled RNA bound is quantified and listed. (**B**) Various nucleic acids oligonucleotides consisting of the first 50 bases of *E. coli* MBP run out on a native polyacrylamide gel. Oligonucleotides were annealed to create various nucleic acids and end labeled with radioactive ^32^P. ssRNA 1, sense MBP 1--50; ssRNA 2, anti-sense MBP 1--50; ssDNA, sense MBP 1--50. (**C**) Representative EMSAs showing the binding of purified MBP-SUV39H1 1--106 and to various nucleic acids, all composed of the *E. coli* MBP 1--50 sequence, shown in B. Protein is diluted 2-fold from 25 μM. Quantification in [Figure 3E](#fig3){ref-type="fig"}. (**D**) Left, binding curves showing binding of MBP-SUV39H1 1--106 and either sense or anti-sense 19mer ssRNA, protein diluted 2-fold from 100 µM. Error bars are standard deviation from two independent experiments. Right, dissociation constants (K~d~, μM) determined by non-linear fitting of the binding curves. Standard error represents the error of the curve fitting to the average of two experimental replicates. (**E**) Representative EMSAs showing binding of purified MBP-SUV39H1 1--106 to 180 bases of either α-satellite or β-actin ssRNA. Protein diluted 2-fold from 2.5 μM. Quantification in [Figure 3F](#fig3){ref-type="fig"}. (**F**) SUV39H1 affinity increases as length of nucleic acid increases. Binding curves compiled from [Figure 3E and F](#fig3){ref-type="fig"} (50mers and 180mers, respectively) and **D**) (19mers) showing the binding of MBP-SUV39H1 1--106 to various nucleic acid types. 19mer random sequence: sense and antisense ssRNA; 50mer MBP 1--50: sense and antisense ssRNA, ssDNA, dsRNA, dsDNA, and RNA/DNA hybrid; 180mers: α-satellite and β-actin ssRNA. All sequences are described in the materials and methods. Error bars are standard deviation from two independent experiments. Dissociation constants (K~d~, μM) displayed on graph are determined by non-linear fitting of the binding curves. Standard error represents the error of the curve fitting to the average of two experimental replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.009](10.7554/eLife.25299.009)

SUV39H1 can bind multiple nucleic acid types with minimal sequence preference {#s2-5}
-----------------------------------------------------------------------------

To determine if purified SUV39H1 exhibited a binding preference for different types of nucleic acids, we tested its binding to ssRNA, ssDNA, dsRNA, dsDNA and RNA/DNA hybrids using 50 nucleotides of the *E. coli* MBP sequence to generate each nucleic acid type ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). We found that SUV39H1 1--106 bound to all five types of nucleic acids with similar affinities, ranging from 61 ± 5 nM for ssRNA to 185 ± 17 nM for dsDNA ([Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). SUV39H1 1--106 bound to the sense and antisense strand of MBP 1--50 ssRNA with similar affinities (61 ± 5 nM ssRNA1 vs. 64 ± 3 nM ssRNA2) ([Figure 3E](#fig3){ref-type="fig"}), and showed a 2.5-fold difference in affinity for the sense and anti-sense 19mer ssRNA used in [Figure 3C and D](#fig3){ref-type="fig"} (145 ± 9 nM sense vs. 366 ± 22 nM anti-sense) ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}).

The pericentric regions of human chromosomes are composed of repetitive α-satellite DNA sequences, which are weakly transcribed in humans ([@bib38]; [@bib86]). Because SUV39H1 localizes to pericentric regions ([@bib1]) and we detected chromosome-associated α-satellite RNA at these sites ([Figure 1C and D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}), we tested whether SUV39H1 preferentially binds to α-satellite RNA. We measured SUV39H1 binding to a ssRNA containing a single monomeric unit of α-satellite (180 nucleotides), compared to a segment of β-actin mRNA of equal length. We found that SUV39H1 1--106 bound α-satellite or β-actin RNA with similar affinities: 23 ± 2 nM and 32 ± 2 nM, respectively ([Figure 3F](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). This is consistent with the sequence-independent binding we observed for 19mer and 50mer ssRNA oligonucleotides. We conclude that SUV39H1 can bind both double- and single-stranded nucleic acids, has minimal sequence preference for the sequences tested thus far, and that binding affinity increases with increasing nucleic acid length ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}).

Identification of SUV39H1 RNA binding deficient mutants {#s2-6}
-------------------------------------------------------

Our observation that RNA is bound to pericentric heterochromatin at the same sites where SUV39H1-dependent histone methylation occurs suggests that direct RNA binding may regulate the localization and function of SUV39H1. Recent studies have proposed that direct RNA binding by SUV39H1 is necessary for its localization to specific genomic locations ([@bib67]; [@bib76]), but this model has not been tested directly. To test whether RNA binding by SUV39H1 controls its interaction with chromatin, we identified RNA binding deficient mutants of SUV39H1 by alanine-scanning mutagenesis of the SUV39H1 chromodomain (42-106) ([Figure 4---figure supplement 1A and B](#fig4s1){ref-type="fig"}). We identified mutants that either decreased (12 mutants) or increased (11 mutants) the affinity of SUV39H1 for ssRNA more than 10-fold when compared to the wild-type (WT) SUV39H1 chromodomain ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Interestingly, 6 of the 12 mutants that decreased RNA binding affinity removed a positively charged residue (R or K), and 7 of the 11 mutants that increased RNA binding removed a negatively charged residue (D or E) ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). By performing a more comprehensive analysis of the binding of these 23 mutants ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}), we discovered two mutations, R55A and R84A, that almost completely abolished RNA binding by SUV39H1, reducing the affinity over 40-fold compared to WT ([Figure 4C](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C and D](#fig4s1){ref-type="fig"}).10.7554/eLife.25299.010Figure 4.Identification and biochemical characterization of SUV39H1 RNA binding-deficient mutants.(**A**) Identification of SUV39H1 mutants that affect RNA binding. Binding curves from second round of EMSA screening showing the binding of purified MBP-SUV39H1 42--106 point mutants to 19mer RNA (table of measured dissociation constants in [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). (**B**) Crystal structures of the chromodomains of human SUV39H1 (aa 44--91) ([@bib85]) and human HP1α (aa 18--68) bound to H3K9me3 peptide (yellow) ([@bib44]). Residues in SUV39H1 important for RNA binding (red and blue) or H3K9me3 binding (green and orange) are highlighted. The H3K9me3 peptide was co-crystalized with HP1α, but not SUV39H1. (**C**) Quantification of WT SUV39H1, SUV39H1^R55A^, and SUV39H1^R84A^ binding to 19mer RNA. Binding curves generated by quantifying filter binding assays shown in [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}. Error bars are standard deviation from three independent experiments. Dissociation constants (K~d~, μM) displayed on graph are determined by non-linear fitting of the binding curves. Standard error represents the error of the curve fitting to the average of the three experimental replicates. (**D**) Coomassie stained gel of purified MBP-SUV39H1 42--106 proteins -- WT, F43A, R55A, or R84A. (**E**) Binding of SUV39H1 mutants to H3K9me3. Representative α-MBP western blot showing the amount of purified MBP-SUV39H1 42--106 protein, WT or indicated mutant, bound to streptavidin beads conjugated to either H3K9me0 (me0), H3K9me3 (me3), or no peptide (-) added. (**F**) Quantification of western blot shown in 4E, error bars are standard deviation, n = 3, \*p\<0.03. See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.010](10.7554/eLife.25299.010)10.7554/eLife.25299.011Figure 4---figure supplement 1.In vitro characterization of SUV39H1 chromodomain mutants.(**A**) Coomassie stained gels showing purified MBP-SUV39H1 42--106 alanine point mutants. Percent full length protein calculated by dividing (signal of the top band) / (signal of the top band + signal of the bottom band). Res. \#, residue number; res. \> A, residue mutated to alanine; % full, percent full-length protein. (**B**) Table displaying the results from the first round of EMSA screening to measure the binding of MBP SUV39H1 42--106 to a random 19mer ssRNA (sense). Dissociation constants (K~d~, μM) displayed on graph are determined by non-linear fitting of the binding curves. Standard error represents the error of the curve fitting to one experiment consisting of 6 protein concentrations analyzed for each mutant. Highlighted mutants (yellow) have either 10-fold greater or less RNA binding affinity compared to WT, and were re-measured in the second round of EMSAs ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). (**C**) Table showing dissociation constants (K~d~, μM), standard error, Hill slope, and affinity fold-change compared to WT SUV39H1, of point mutants during the second round of EMSAs. Standard error represents the error of the curve fitting to one experiment consisting of 9 protein concentrations analyzed for each mutant and three independent experiments for WT SUV39H1. (**D**) Representative filter binding assay measuring RNA binding of WT SUV39H1, SUV39H1^R55A^, and SUV39H1^R84A^ to random sense 19mer RNA. Quantification shown in [Figure 4C](#fig4){ref-type="fig"}. Purified proteins shown in [Figure 4D](#fig4){ref-type="fig"}, diluted 2-fold from 200 μM. (**E**) Histone methyltransferase assay comparing the activity of WT SUV39H1 to SUV39H1 point mutants. Full length purified MBP-SUV39H1 was incubated with purified H3/H4 tetramer and radioactive methyl donor (^14^C S-adenosyl methionine), +/- RNA, then run on a denaturing gel. Histone H3 methylation was detected with a phosphorimager (top panels), and proteins were visualized by Coomassie staining (bottom panels).**DOI:** [http://dx.doi.org/10.7554/eLife.25299.011](10.7554/eLife.25299.011)

Because SUV39H1 can bind all nucleic acids with comparable affinities, it is likely that the R55A and R84A mutations that disrupt RNA binding also prevent binding to DNA. Therefore, we refer to these mutations as nucleic acid binding mutations.

Mutational separation of nucleic acid binding from methylated histone recognition {#s2-7}
---------------------------------------------------------------------------------

The chromodomains of HP1 proteins specifically recognize methylated H3K9 through three conserved aromatic residues, called the 'aromatic cage' ([@bib7]; [@bib39]; [@bib48]; [@bib61]). The SUV39H1 chromodomain also specifically binds to methylated H3K9 peptides, most likely via three similar aromatic cage residues ([Figure 4B](#fig4){ref-type="fig"}) ([@bib85]). The R55A and R84A mutations that disrupt nucleic acid binding are distant from the aromatic cage in the 3D structure of SUV39H1, and thus we hypothesized that they do not affect H3K9me3 binding ([Figure 4B](#fig4){ref-type="fig"}) ([@bib85]). We tested this by measuring the binding of WT and mutant SUV39H1 chromodomains to unmethylated (me0) or trimethylated (me3) H3K9 peptides ([Figure 4D,E and F](#fig4){ref-type="fig"}). As previously reported, we found that the WT SUV39H1 chromodomain preferentially binds to H3K9me3 compared to H3K9me0, and this binding is completely disrupted by the aromatic cage mutant SUV39H1^F43A^ ([Figure 4E and F](#fig4){ref-type="fig"}) ([@bib85]). Importantly, neither of the nucleic acid binding mutants (SUV39H1^R55A^ and SUV39H1^R84A^) alter the binding of SUV39H1 to H3K9me3 ([Figure 4E and F](#fig4){ref-type="fig"}). We conclude that SUV39H1^R55A^ and SUV39H1^R84A^ mutants specifically disrupt the interaction between SUV39H1 and nucleic acids without perturbing binding to H3K9me3.

We also confirmed that the R55A, R84A, and F43A mutations had no effect on the methyltransferase activity of full-length SUV39H1 ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). Interestingly, the addition of RNA inhibits SUV39H1 activity, as has been previously shown for PRC2 and several other SET domain histone methyltransferases ([@bib20]; [@bib42]). However, SUV39H1 nucleic acid binding mutants were equally inhibited by RNA, suggesting that this inhibition is largely independent of direct RNA binding.

SUV39H1 associates with α-satellite RNA in human cells {#s2-8}
------------------------------------------------------

Our observations that RNA is associated with pericentric heterochromatin and that SUV39H1 directly binds RNA in vitro prompted us to test if SUV39H1 associates with RNA in human cells. In SUV39H1-GFP expressing HeLa cells, SUV39H1 colocalizes with EU-labeled RNA at pericentric regions of mitotic chromosomes ([Figure 5A](#fig5){ref-type="fig"}). To test if SUV39H1 can bind to α-satellite RNA, we expressed GFP-tagged WT SUV39H1, the nucleic acid binding deficient mutant SUV39H1^R55A^, or GFP alone under doxycycline inducible control. We then crosslinked the cells with formaldehyde, immunoprecipitated the GFP-tagged protein, and analyzed SUV39H1-associated RNAs by reverse transcription followed by quantitative PCR (RT-qPCR). We found that α-satellite RNA was enriched in the WT SUV39H1 IP 13 ± 2 fold when compared to GFP alone ([Figure 5B and C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) and that R55A mutation reduced the amount of α-satellite RNA to 45 ± 16% of the levels bound to WT ([Figure 5C](#fig5){ref-type="fig"}). The expression of WT SUV39H1 or SUV39H1^R55A^ did not lead to changes in total α-satellite RNA levels in the presence of endogenous SUV39H1, indicating that the difference in immunoprecipitated α-satellite RNA was not due to changes in the overall levels of α-satellite RNA ([Figure 5D](#fig5){ref-type="fig"}). In addition, the R55A mutation did not disrupt SUV39H1's association with HP1α, indicating that α-satellite RNA binding to SUV39H1 is not occurring indirectly through HP1α ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). These results demonstrate that SUV39H1 associates with α-satellite RNA in cells, and that this association is facilitated by the nucleic acid binding activity of the SUV39H1 chromodomain.10.7554/eLife.25299.012Figure 5.SUV39H1 association with α-satellite RNA in vivo depends on direct nucleic acid binding.(**A**) Colocalization of SUV39H1 and RNA at pericentric regions. SUV39H1-GFP expressing HeLa cells were labeled with EU and induced with doxycycline for 6 hr, then mitotic cells were spun onto coverslips. Cells were stained for DNA (blue), with anti-GFP to detect SUV39H1-GFP (green), for EU-RNA (red), and CENP-A to mark centromeres. (**B**) Silver stained gel showing protein immunoprecipitated by an anti-GFP antibody from cell lines expressing GFP, SUV39H1-GFP, or SUV39H1^R55A^-GFP. (**C**) Quantification of α-satellite RNA immunoprecipitated with SUV39H1. RNA was isolated from IPs, and RT-qPCR was performed to detect α-satellite RNA sequence. Enrichment values are the ratio of α-satellite/β-actin RNA in the IP over the ratio of α-satellite/β-actin RNA in total lysate, normalized to the GFP values. Error bars are standard error, n = 3, \*p\<0.04. (**D**) Total α-satellite RNA levels in GFP, SUV39H1-GFP, and SUV39H1^R55A^-GFP cell lines, divided by the amount of β-actin RNA, normalized to the GFP values. See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.012](10.7554/eLife.25299.012)10.7554/eLife.25299.013Figure 5---figure supplement 1.Immunoprecipitation of SUV39H1-GFP from human cells.(**A**) Anti-GFP western blot of total input lysate (T), lysate after IP depletion (D), and IP samples (IP) from three different HeLa Flp-In T-REx cell lines. RNA was purified from anti-GFP immunoprecipitated material and analyzed by RT-qPCR ([Figure 5](#fig5){ref-type="fig"}). (**B**) Anti-SUV39H1 and anti-HP1α western blot of total input lysate (T), lysate after IP depletion (D), and IP samples (IP) from three different HeLa Flp-In T-REx cell lines, after performed RIP protocol immunoprecipitation.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.013](10.7554/eLife.25299.013)

SUV39H1 relies on direct RNA binding for its localization to pericentric heterochromatin {#s2-9}
----------------------------------------------------------------------------------------

To test how the SUV39H1 chromodomain interactions with RNA and H3K9me3 contribute to its localization in human cells, we measured the extent of localization of GFP-tagged WT or mutant SUV39H1 on spread mitotic chromosomes. The R55A and R84A nucleic acid binding mutants of SUV39H1 showed defects in localization, reducing SUV39H1 signal by about half (R55A: 42 ± 8% of WT levels, R84A: 45 ± 9% of WT levels) ([Figure 6A, B and C](#fig6){ref-type="fig"}); indicating that the direct interaction of SUV39H1 with nucleic acids is important for its localization to pericentric heterochromatin. We also found that the aromatic cage mutants W64A and F43A led to more pronounced localization defects than those caused by the nucleic acid binding mutants (W64A: 10 ± 4% of WT levels, F43A: 15 ± 5% of WT levels) ([Figure 6A, B and C](#fig6){ref-type="fig"}). These results suggest that both H3K9me3 binding and nucleic acid binding contribute to SUV39H1 localization to pericentric heterochromatin during mitosis.10.7554/eLife.25299.014Figure 6.Direct nucleic acid binding by SUV39H1 regulates its localization on mitotic chromosomes.(**A**) Localization of WT or mutant SUV39H1-GFP on human mitotic chromosomes. Expression of SUV39H1-GFP was induced in HeLa cell lines for 6 hr, then mitotic cells were spun onto coverslips and stained for DNA (blue), with anti-GFP to detect SUV39H1-GFP (green), and for HEC1 to mark centromeres (red). Shown are representative images. (**B**) Western blot assessing expression of inducible SUV39H1-GFP in HeLa cell lines after 6 hr of +/- doxycycline induction. (**C**) Quantification of SUV39H1-GFP levels at pericentric regions, from experiment shown in 6A. Each experiment was normalized to the WT measurement. Bars show the average of n = 3 separate experiments, 15 cells quantified per condition per experiment, error bars represent standard error. (**D**) Localization of WT or mutant SUV39H1-GFP on human mitotic chromosomes after RNase treatment. Mitotic HeLa cells expressing SUV39H1-GFP (WT or R55A) were spread onto coverslips and incubated without RNase, with RNase A, or with RNase A plus RNase inhibitors. Cells were then stained for DNA (blue), anti-GFP to detect SUV39H1 (green), and HEC1 to mark centromeres (red). Shown are representative images. (**E**) Quantification of SUV39H1-GFP levels at pericentric regions after RNase treatment, from experiment shown in 6D. Each experiment was normalized to the untreated WT measurement. Shown are the averages of n = 5 separate experiments, 15 cells quantified per condition per experiment, error bars represent standard error. See also [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.014](10.7554/eLife.25299.014)10.7554/eLife.25299.015Figure 6---figure supplement 1.HP1α localization correlates with SUV39H1 localization, despite no change in H3K9me3 levels.(**A**) Representative images of HP1α and SUV39H1-GFP localization on HeLa mitotic chromosomes after RNase treatment. Expression of SUV39H1-GFP was induced or not for 6 hr (+/- dox), then mitotic cells were spun onto coverslips and incubated without RNase, with RNase A, or with RNase A plus RNase inhibitors. Cells were then stained for DNA (blue), with an anti-GFP antibody to detect SUV39H1-GFP, HP1α (green), and HEC1 to mark centromeres (red). (**B**) Quantification of HP1α at pericentric regions from experiment shown in A. Each experiment was normalized to the untreated -dox measurement. Bars are the average of n = 5 separate experiments, 15 cells quantified per condition per experiment, error bars represent standard error. (**C**) Quantification of H3K9me3 at pericentric regions in HeLa cells with or without exogenous expression of SUV39H1-GFP for 6 hr (+/- dox). Bars are the average of n = 3 separate experiments, 15 cells quantified per condition per experiment, error bars represent standard error. (**D**) HP1α localization is reduced in cells expressing mutant SUV39H1-GFP compared to cells expressing WT SUV39H1-GFP. Expression of SUV39H1-GFP, WT or mutants, was induced or not for 6 hr (-/+ dox) in HeLa Flp in TREx cell lines. Mitotic cells were spun onto coverslips and stained for DNA (blue), HP1α (green), and HEC1 to mark centromeres (red). (**E**) Quantification of HP1α at pericentric regions from experiment shown in D. Each experiment was normalized to the wildtype measurement. Bars are the average of n = 5 separate experiments, 15 cells quantified per condition per experiment, error bars represent standard error. P values were calculated with paired, two-tailed t tests.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.015](10.7554/eLife.25299.015)

To specifically test the contribution of RNA to SUV39H1 localization, we digested mitotic chromosomes with RNase A, a treatment we previously observed removed both pericentric RNA ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) and WT SUV39H1 ([Figure 2A and B](#fig2){ref-type="fig"}) from chromosomes. RNase A treatment reduced the pericentric localization of SUV39H1 to 43 ± 4% of the undigested control, similar to the levels of the untreated SUV39H1^R55A^ mutant in the same experiments (52 ± 9% of WT) ([Figure 6D and E](#fig6){ref-type="fig"}). This indicates that the effect of the R55A mutation on SUV39H1 localization can be fully attributed to a loss in RNA binding, independent of DNA binding. This is further supported by the fact that RNase A treatment did not significantly reduce the amount of SUV39H1^R55A^ at pericentric chromatin (untreated: 52 ± 9%, RNase A: 42 ± 5%) ([Figure 6D and E](#fig6){ref-type="fig"}). Taken together, these results demonstrate that direct binding to both chromosome-associated RNA and H3K9me2/3 are required for proper localization of SUV39H1 to pericentric heterochromatin.

SUV39H1 can recruit HP1α to pericentric heterochromatin independently of H3K9 methylation {#s2-10}
-----------------------------------------------------------------------------------------

Previous studies found that HP1α localization at heterochromatin is sensitive to RNase treatment in both mouse interphase cells and on human mitotic chromosomes ([@bib51]; [@bib86]). We also observed a reduction in HP1α levels on chromatin after RNase A treatment, to 77 ± 13% of control levels ([Figure 6---figure supplement 1A and B](#fig6s1){ref-type="fig"}). We wondered if the RNase sensitivity of HP1α could be due in part to its interaction with SUV39H1. Consistent with this, expressing SUV39H1-GFP for 6 hr, which causes an increase in SUV39H1-GFP at pericentric regions, also caused a 1.5-fold increase in HP1α localization ([Figure 6---figure supplement 1A and B](#fig6s1){ref-type="fig"}), in the absence of any detectable change in H3K9me3 levels ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). Additionally, we observed that RNase A treatment abolished the increase in HP1α localization following exogenous SUV39H1-GFP expression ([Figure 6---figure supplement 1A and B](#fig6s1){ref-type="fig"}). Finally, after expressing SUV39H1 mutants, the extent of HP1α localization positively correlated with SUV39H1 localization ([Figure 6A and C](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1D and E](#fig6s1){ref-type="fig"}). These results are consistent with a model in which the pericentric localization of HP1α during mitosis depends on the SUV39H1 protein -- independent of H3K9 methylation -- and that HP1α localization is sensitive to RNase treatment because SUV39H1 localization depends on direct binding to RNA.

SUV39H1 depends on direct nucleic acid binding for its stable association with heterochromatin {#s2-11}
----------------------------------------------------------------------------------------------

The requirement for RNA for SUV39H1 localization in mitosis suggests that RNA binding might generally stabilize the interaction of SUV39H1 with chromatin. To assess this in interphase cells, we measured the turnover rate of GFP-tagged WT SUV39H1, SUV39H1^R55A^, SUV39H1^R84A^, SUV39H1^F43A^, and SUV39H1^W64A^ using fluorescence recovery after photobleaching (FRAP) ([Figure 7A, B and C](#fig7){ref-type="fig"}). After photobleaching, WT SUV39H1 recovered with an average half-time of 27 ± 7 s ([Figure 7D](#fig7){ref-type="fig"}), with a stable, immobile fraction of SUV39H1 that did not recover during the time frame of our experiment ([Figure 7B, C and E](#fig7){ref-type="fig"}). The mobile fraction represented 58 ± 7% of the total nuclear SUV39H1 ([Figure 7E](#fig7){ref-type="fig"}), consistent with previous measurements ([@bib35]; [@bib47]). The aromatic cage mutants SUV39H1^W64A^ ([Figure 7B](#fig7){ref-type="fig"}) and SUV39H1^F43A^ ([Figure 7C](#fig7){ref-type="fig"}), which disrupt binding to H3K9me3, had a much faster recovery half-time of 6 ± 2 and 5 ± 1 s, respectively ([Figure 7D](#fig7){ref-type="fig"}). Unlike WT SUV39H1, approximately 90--95% of each aromatic cage mutant was determined to be mobile within the nucleus ([Figure 7E](#fig7){ref-type="fig"}). Together, this high level of mobility and rapid recovery is consistent with weak and/or transient associations with chromatin that are normally stabilized by SUV39H1's interaction with methylated histones.10.7554/eLife.25299.016Figure 7.SUV39H1 depends on direct nucleic acid binding for its stable association with chromatin in interphase cells.(**A**) Fluorescence recovery after photobleaching (FRAP) assay to measure SUV39H1-GFP association with chromatin. Montage of images of representative cells expressing either WT or mutant SUV39H1-GFP, as indicated, in our FRAP assay. Leftmost panel shows the ROIs used for quantification and analysis, with the innermost circle representing the diameter of the photobleached area. (**B, C**) Quantification of SUV39H1-GFP recovery after photobleaching. The fluorescence intensity of the bleached area was normalized relative to the whole nucleus, and plotted as a function of time for WT (gray, n = 19), R55A (red, n = 19), W64A (green, n = 23), R84A (blue, n = 23) and F43A (orange, n = 35) mutants. Black lines are the average between individual traces and colored shading represents standard deviation. WT curves are shown in both panels for clarity. (**D**) Half-time to recovery measurements from SUV39H1-GFP FRAP traces. Individual traces (averages shown in 7B and 7C) were fit to a single exponential, and the half-time to recovery for each curve was plotted for WT and mutant SUV39H1-GFP cells. (**E**) Quantification of the mobile fraction of SUV39H1-GFP. Bar graph of the mean amplitude of the curves from 7B and 7C. Error bars represent standard deviation. The differences between mobile fractions are statistically significant (p\<0.01), except between R55A and R84A. (**F**) Half-time to recovery measurements from SUV39H1-GFP FRAP traces, in the presence of the RNA Pol I inhibitor CX5461. Individual traces were fit to a single exponential, and the half-time to recovery for each curve was plotted for WT and mutant SUV39H1-GFP cells. (**G**) Quantification of the mobile fraction of SUV39H1-GFP, in the presence of the RNA Pol I inhibitor CX5461. Bar graph of the mean amplitude of recovery curves. Error bars represent standard deviation. See also [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.016](10.7554/eLife.25299.016)10.7554/eLife.25299.017Figure 7---figure supplement 1.Effect of transcription inhibition on SUV39H1 fluorescence recovery, and model for RNA-dependent retention of SUV39H1 at heterochromatin.(**A**) Half-time to recovery measurements from SUV39H1-GFP FRAP traces, in the presence of two different RNA Pol II inhibitors, α-amanitin and triptolide. Individual traces were fit to a single exponential, and the half-time to recovery for each curve was plotted for WT and mutant SUV39H1-GFP cells. (**B**) Quantification of the mobile fraction of SUV39H1-GFP, in the presence of two different RNA Pol II inhibitors, α-amanitin and triptolide. Bar graph of the mean amplitude of recovery curves. Error bars represent standard deviation. (**C**) Model for RNA-dependent localization of SUV39H1. Left: WT SUV39H1 binds both H3K9me3 and RNA through via its chromodomain (CD), and these interactions properly localize SUV39H1 to heterochromatin. The SET domain of SUV39H1 (SET) methylates H3K9, and the N-terminus of SUV39H1 (N) helps to recruit HP1α via its chromoshadow domain (CSD). Right: When the interaction between SUV39H1 and RNA is disrupted, either by RNase or by the RNA binding mutants SUV39H1^R55A^ or SUV39H1^R84A^, the association of SUV39H1 with heterochromatin is weakened. Although SUV39H1 can still bind H3K9me2/3, SUV39H1's interaction with chromatin is more unstable and dynamic, and the levels of both SUV39H1 and HP1α bound to heterochromatin are reduced.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.017](10.7554/eLife.25299.017)

Interestingly, the nucleic acid binding deficient mutants SUV39H1^R55A^ ([Figure 7B](#fig7){ref-type="fig"}) and SUV39H1^R84A^ ([Figure 7C](#fig7){ref-type="fig"}) showed an average recovery time in between that of WT SUV39H1 and the H3K9me3 binding mutants, with half-lives of 14 ± 3 and 13 ± 2 s, respectively ([Figure 7D](#fig7){ref-type="fig"}). Consistent with this trend, both SUV39H1^R55A^ and SUV39H1^R84A^ demonstrated a level of mobility (77% ± 6) that was greater than WT SUV39H1, but less than the aromatic cage mutants SUV39H1^W64A^ and SUV39H1^F43A^ ([Figure 7E](#fig7){ref-type="fig"}). We noted that the sub-nuclear localization of the aromatic cage mutants was more diffuse, and generally lacking the typical heterochromatin centers observed in the WT SUV39H1, SUV39H1^R55A^ and SUV39H1^R84A^ cell lines ([Figure 7A](#fig7){ref-type="fig"}). Combined with our in vitro biochemical analysis, these observations support a model in which direct binding to nucleic acids stabilizes the association of SUV39H1 with chromatin in interphase cells as well as in mitosis.

If RNA stabilizes SUV39H1 on chromatin, then inhibiting RNA transcription to reduce the levels of chromatin-associated RNA is expected to destabilize SUV39H1 localization. When we added the RNA Pol I inhibitor CX-5461 -- a treatment that we saw reduces RNA localization on mitotic chromosomes ([Figure 1---figure supplement 2A and B](#fig1s2){ref-type="fig"}) -- the fluorescence recovery half-time of WT SUV39H1 decreased from 27 ± 7 s to 16 ± 3 s, comparable to the half-time of the nucleic acid binding mutant SUV39H1^R55A^ ([Figure 7F](#fig7){ref-type="fig"}). However, we also observed a slight effect of Pol I inhibition on SUV39H1^R55A^, with a decrease in half-time from 14 ± 3 to 11 ± 2 s. This suggests that RNA polymerase inhibition may have non-specific effects on SUV39H1 localization in addition to disrupting SUV39H1 binding to chromatin through chromatin-associated RNAs. We also saw similar effects with α-amanitin or triptolide treatment ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}), suggesting that Pol II may also be playing a role in SUV39H1 localization; however, this effect may also be due to the partial inhibition of Pol I with these inhibitors ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). Although polymerase inhibition resulted in measureable changes in the recovery kinetics of SUV39H1, we observed no significant changes in overall SUV39H1 mobility ([Figure 7G](#fig7){ref-type="fig"}).

SUV39H1 interactions with both nucleic acids and H3K9me3 are necessary for proper heterochromatin silencing {#s2-12}
-----------------------------------------------------------------------------------------------------------

Because RNA binding and H3K9me3 binding both contribute to SUV39H1 localization, we wanted to determine the effect of disrupting these interactions on SUV39H1-dependent heterochromatic silencing. Using CRISPR/Cas9 genome editing, we generate DLD-1 cell lines in which the endogenous SUV39H1 was altered to contain either a nucleic acid binding mutation (R55A), an H3K9me3 binding mutation (F43A) or both (R55A/F43A) ([Figure 8A](#fig8){ref-type="fig"}). We made these SUV39H1 mutations in a SUV39H2 knockout background to prevent redundant activities of SUV39H2 from masking effects of these mutations. We found that total H3K9me3 levels, as well as H3K9me3 localization at centromeres, were reduced in all SUV39H1 mutants compared to WT SUV39H1 ([Figure 8B, C, D and E](#fig8){ref-type="fig"}), demonstrating a role for both H3K9me3 binding and nucleic acid binding by SUV39H1 in maintaining normal H3K9 methylation levels. To assess the role of SUV39H1 nucleic acid binding and H3K9me3 binding in repressing pericentromeric heterochromatin, we measured α-satellite RNA levels in the WT and mutant SUV39H1 cell lines. We found that α-satellite expression increased 1.35-fold, 1.56-fold, and 2.10-fold, in the R55A, F43A, and the R55A/F43A double mutant cells lines, respectively, compared to WT ([Figure 8F](#fig8){ref-type="fig"}). Interestingly, although no change in H3K9me3 was detected between the F43A single mutant and the R55A/F43A double mutant ([Figure 8C and D](#fig8){ref-type="fig"}), a significant increase in α-satellite RNA levels was observed in R55A/F43A compared to F43A ([Figure 8F](#fig8){ref-type="fig"}), indicating that SUV39H1 nucleic binding may make H3K9me3-independent contributions to heterochromatin function. Importantly, because the defects in SUV39H1 localization caused by the R55A nucleic acid binding mutation were similar to defects caused by RNase treatment or RNA polymerase inhibition ([Figure 6E](#fig6){ref-type="fig"}, [Figure 7](#fig7){ref-type="fig"}), we support a model in which the heterochromatin defects we observe with this mutant are due to breaking interactions with chromatin-associated RNA. Taken together, these data demonstrate that both RNA binding and H3K9me3 binding by SUV39H1 contribute to silencing of constitutive heterochromatin in human cells.10.7554/eLife.25299.018Figure 8.Nucleic acid binding and H3K9me3 binding both contribute to SUV39H1-mediated constitutive heterochromatin silencing.(**A**) Sanger DNA sequencing traces showing point mutations in the endogenous SUV39H1 locus in DLD-1 cells, generated by CRISPR/Cas9 gene editing. (**B**) Representative western blot showing H3K9me3, histone H4, SUV39H1, and HP1α levels in normal unedited DLD-1 cells (far left), or SUV39H2 KO DLD-1 cells with the indicated mutations in SUV39H1. (**C**) Total H3K9me3 levels in mutant SUV39 DLD-1 cells, measured by quantitative western blot. Nuclear lysate was prepared and blotted with indicated antibodies, and H3K9me3 signal was normalized to histone H4 levels. Graphed are the means of 3 repeats, errors bars represent standard error. (**D**) Quantification of H3K9me3 localization at centromeres in mutant SUV39 DLD-1 cells. Cells were grown on coverslips, fixed and permeabilized, then stained with the indicated antibodies, imaged, and quantified using centromere finder software, using CREST staining as a centromere marker. Graphed are the means of 4 repeats, error bars represent standard error. Significance was determined using paired, two-tailed t-tests. \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005. (**E**) Representative images of immunofluorescence staining of mutant SUV39 DLD-1 cells, used for quantification shown in 8D. Cells are stained for DNA (blue), H3K9me3 (green), and CREST centromere stain (red). (**F**) Quantification of α-satellite RNA in mutant SUV39 DLD-1 cells by RT-qPCR. Total α-satellite RNA levels are normalized to GAPDH RNA levels. Graphed are the means of 3 repeats, error bars represent standard error. Significance was determined using paired, two-tailed t-tests. \*p\<0.05, \*\*p\<0.005.**DOI:** [http://dx.doi.org/10.7554/eLife.25299.018](10.7554/eLife.25299.018)

Discussion {#s3}
==========

Several models have been proposed for how chromatin-associated RNAs regulate the organization and transcription of the genome ([@bib20]; [@bib22]; [@bib42]; [@bib45]; [@bib72]). One emerging theme is that chromatin-associated RNAs help to localize chromatin-modifying proteins, either by recruiting them to target loci in trans ([@bib46]; [@bib89]; [@bib91]) or by stabilizing their interactions with chromatin in cis ([@bib51], [@bib52]; [@bib78]). Here, we demonstrate that α-satellite RNAs are attached to the pericentric regions of human mitotic chromosomes in cis. These RNAs regulate the localization of the histone methyltransferase SUV39H1 via a direct protein-RNA interaction, ensuring the stable association of SUV39H1 with pericentric heterochromatin.

α-satellite RNA at human pericentric heterochromatin {#s3-1}
----------------------------------------------------

We show for the first time that RNAs associated with mitotic chromosomes are enriched at pericentric regions in several human cell lines ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Previous studies have shown that transcription by RNA polymerase II (Pol II) can occur at the centromeres of human mitotic chromosomes ([@bib16]; [@bib50]). The RNA we observe is distinct from this previously described centromeric RNA in that its localization is insensitive to Pol II inhibition ([Figure 1---figure supplement 2A and B](#fig1s2){ref-type="fig"}), and exhibits broader pericentric localization. RNA FISH shows that the RNA we observe is transcribed from pericentric α-satellite sequences outside of the core centromere region ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}). Additionally, the α-satellite RNAs we detect are associated in cis with the chromosomes from which they are transcribed ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1F and G](#fig1s1){ref-type="fig"}), supporting the idea that their localization may provide direct feedback on the local transcriptional state. This differs from the phenomenon observed in *Drosophila* cells, where SAT III RNA transcribed from the X chromosome localizes to all centromeres in trans ([@bib74]).

It is interesting that we observe RNA on mitotic chromosomes, as transcription is silenced during mitosis ([@bib30]), and known noncoding RNAs, such as Xist, dissociate from chromatin during mitosis in human cells ([@bib37]). This may reflect the particular importance of centromeric and pericentric RNA in maintaining chromatin structure around the centromere for chromosome cohesion and proper chromosome segregation during mitosis ([@bib23]; [@bib55]; [@bib64]). Centromeric and pericentric RNAs have been proposed to play functional roles in several different organisms ([@bib10]; [@bib15]; [@bib18]; [@bib32]; [@bib68]; [@bib74]), and the transcription of repetitive α-satellite sequences at human centromeres has been implicated in maintaining centromere identity ([@bib16]; [@bib69]; [@bib86]), regulating the mitotic kinase Aurora B ([@bib25]; [@bib38]; [@bib40]; [@bib53]), and influencing chromosome stability ([@bib92]) and cohesion ([@bib50]). RNAs encoded by pericentric DNA may maintain their association with mitotic chromosomes to regulate these processes, and may interact with chromatin in a manner that is distinct from other regulatory RNAs that dissociate from chromatin during mitosis.

Characterization of the SUV39H1-RNA interaction {#s3-2}
-----------------------------------------------

We find that the human SUV39H1 protein directly binds to RNA through its chromodomain. This is consistent with the identification of other chromodomain-containing proteins that bind RNA ([@bib2]) and the interaction of the SUV39H1 chromodomain with TERRA RNA ([@bib67]). However, we also detect binding of SUV39H1 to other types of nucleic acid species (dsDNA, ssDNA, dsRNA, RNA:DNA) ([Figure 3E](#fig3){ref-type="fig"}), observe no strong preference for any sequence tested ([Figure 3E and F](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), and see a positive correlation between nucleic acid length and binding affinity ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). Additionally, we find that a loss of positively charged residues generally decreases SUV39H1-RNA affinity, whereas a loss of negatively charged residues generally increases SUV39H1-RNA affinity ([Figure 4---figure supplement 1B and C](#fig4s1){ref-type="fig"}). One hypothesis that accounts for these observations is that binding occurs via electrostatic interactions between the negatively charged phosphate backbone of nucleic acids and the positively charged residues within the SUV39H1 chromodomain.

It is notable that the Polycomb Repressive Complex 2 (PRC2) also exhibits relatively promiscuous, length-dependent, sequence-independent RNA binding; though specificity for certain RNA sequences can be observed in vivo and in vitro ([@bib22], [@bib21]). It is possible that for SUV39H1 and PRC2, and potentially for other chromatin modifiers, RNA binding may generally stabilize interactions with chromatin rather than target the proteins to specific sites. Although we observe no sequence specificity for binding α-satellite RNA in vitro ([Figure 3F](#fig3){ref-type="fig"}), SUV39H1 associates with α-satellite RNA in human cells, and this interaction is impaired by mutations that disrupt the ability of SUV39H1 to directly bind RNA in vitro ([Figure 5C](#fig5){ref-type="fig"}). It will be important to further explore the specificity of the SUV39H1-RNA interaction, as well as more broadly identify RNAs that associate with SUV39H1 in human cells, as had been done with PRC2 ([@bib22]; [@bib43]).

Role of nucleic acid binding in SUV39H1 localization and function {#s3-3}
-----------------------------------------------------------------

By generating point mutations that separate the nucleic acid binding and H3K9me3 binding functions of the SUV39H1 chromodomain, we assessed the individual contributions of these two interactions on SUV39H1 localization and function. We show for the first time that direct nucleic acid binding contributes to SUV39H1 localization by stabilizing its interaction with heterochromatin, in both interphase and mitotic human cells ([Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}), and that the localization defects we observe in RNA binding mutants of SUV39H1 are largely recapitulated by RNase treatment or RNA polymerase inhibition ([Figures 6D, E](#fig6){ref-type="fig"}, [7F and G](#fig7){ref-type="fig"}); strongly suggesting that SUV39H1 requires direct RNA binding for its stable association with chromatin. Importantly, we demonstrate that breaking the nucleic acid binding of SUV39H1 leads to defects in HP1α localization ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), H3K9me3 methylation ([Figure 8B, C, D and E](#fig8){ref-type="fig"}), and repression of repetitive α-satellite sequences ([Figure 8F](#fig8){ref-type="fig"}).

It is important to note that because of the high conservation between SUV39H1 and HP1α aromatic cages ([Figure 4B](#fig4){ref-type="fig"}), it has been widely hypothesized that an intact aromatic cage is necessary for the localization of SUV39H1 ([@bib85]), but this hypothesis has not been directly assessed. Both aromatic cage mutations of SUV39H1 we tested resulted in an almost complete loss of SUV39H1 localization and retention on chromatin, confirming that binding to H3K9me3 through the aromatic cage is indeed a key determinant of SUV39H1 localization ([Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}).

A model for the RNA-dependent stabilization of SUV39H1 on chromatin {#s3-4}
-------------------------------------------------------------------

It remains a major outstanding question how SUV39H1 specifically recognizes its genomic sites of action. Although it had been originally proposed that HP1 proteins directly recruit SUV39H1 ([@bib7]; [@bib36]; [@bib48]), subsequent studies in fission yeast demonstrated that SUV39/Clr4 localization is largely independent of HP1 proteins ([@bib57]; [@bib75]). A recent study also showed that the N-terminus of mammalian SUV39H1 contributes to its association with chromatin in vitro and in vivo through a zinc-finger like motif thought to directly bind DNA ([@bib59]). However, SUV39H1 binds a variety of repetitive sequences in mammals ([@bib12]) with no apparent DNA consensus sequence, making it unlikely that DNA recognition is the sole factor determining SUV39H1 targeting. In addition, the chromodomain of SUV39H1 has been shown previously to be important for its localization ([@bib55]), but the relative contributions of binding to methylated H3K9 versus other interactions mediated by the chromodomain were not assessed.

Here, we identify both RNA and H3K9me2/3 as main determinants of SUV39H1 localization. Importantly, the RNA-dependent mechanism for SUV39 function appears to be present in both human and mouse cells ([@bib77]; [@bib84]) suggesting a conserved role for RNA in regulating constitutive heterochromatin. A possible advantage to binding chromatin-associated RNA is that it provides direct feedback on the transcriptional state of the locus, ensuring that over-transcribed repeats retain more SUV39H1 to promote repression. Because SUV39H1 displays no apparent sequence preference for binding RNA ([Figure 3E and F](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), it is unlikely that RNA binding alone could confer selective binding for one genomic region over another. It is also unlikely that H3K9me3 binding alone targets SUV39H1, for many H3K9me3 sites exist in the mammalian genome, but not all recruit SUV39H1 ([@bib12]).

We propose a model in which SUV39H1 engages chromatin through several different interactions that in combination define its genomic distribution ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). When direct binding to RNA is disrupted, SUV39H1 can still bind to H3K9me3; however, SUV39H1's interaction with chromatin is destabilized, and its localization at heterochromatin is reduced. RNA binding may help SUV39H1 distinguish between target and non-target sites in the genome that both have H3K9me2/3. In addition to directly binding RNA ([Figure 3](#fig3){ref-type="fig"}) ([@bib67]), H3K9me3 ([Figure 4E and F](#fig4){ref-type="fig"}) ([@bib85]), and DNA ([Figure 3E](#fig3){ref-type="fig"}) ([@bib59]), SUV39H1 also directly binds the deacetylase Sirtuin 1 (SIRT1) ([@bib11]; [@bib83]), and associates with the retinoblastoma tumor suppressor (Rb) protein ([@bib62]; [@bib82]). These and other interactions may influence SUV39H1 recruitment, stable association, and spread on chromatin -- as well as its methyltransferase activity -- to define its sites of action. Thus, a major question going forward is how the collective interactions between SUV39H1 and its binding partners give rise to locus specific targeting and heterochromatin formation. Towards this goal, we have demonstrated that H3K9me2/3 and chromatin-associated RNA are key determinants for SUV39H1 localization and are necessary for maintaining silenced constitutive heterochromatin in human cells.

Materials and methods {#s4}
=====================

Cell culture {#s4-1}
------------

HeLa, U2OS, HFF, HT1080, Huh-7, and primary fibroblasts were grown in Dulbecco's Modified Eagle Medium (DMEM), hTERT-RPE cells were grown in DMEM/F12 media, and DLD-1 cells were grown in RPMI 1640 media. HeLa cells and U2OS cells were acquired from the ATCC. We obtained DLD-1 human colorectal cancer cells from Dr. Daniele Fachinetti and Dr. Don Cleveland, primary fibroblasts from Dr. Paul Khavari, HFF (human foreskin fibroblast) cells from Dr. Matthew Bogyo, HT-1080 fibrosarcoma cells from Dr. Jianghong Rao, hTERT RPE-1 (retina pigmented epithelial) cells from Dr. Tim Stearns, Huh-7 human hepatoma cells from Dr. Peter Sarnow, and Flp-In T-REx HeLa cells from Dr. Pat Brown. These cells were not independently authenticated. Mycoplasma contamination was monitored frequently by cytoplasmic DAPI staining. All cells were grown under American Tissue Culture Collection (ATCC) standard conditions. All media was purchased from Thermo Fisher and supplemented with 10% vol/vol FBS and 100 U/ml penicillin and streptomycin.

Generation of engineered human cell lines {#s4-2}
-----------------------------------------

Flp-In T-REx HeLa cell lines expressing SUV39H1-GFP proteins were made by co-transfecting pOG44 Flp-recombinase expression vector and pcDNA5/FRT/TO tet inducible Flp-In cloning vector (Invitrogen) containing SUV39H1-GFP sequences (ASP 1751, 2137, 2668, 2663, 2670, 2789) using Fugene 6 (Promega). After 48--72 hr, cells were selected with 350 μg/mL hygromycin B (Invitrogen) and 15 μg/mL blasticidin S (Invivogen) until visible colonies formed, then the entire selected population of cells was saved.

SUV39 DKO cells were generated essentially as described ([@bib70]). Briefly, HeLa or DLD-1 cells were transfected with pX458 (pSpCas9(BB)−2A-GFP) containing SUV39H1 and SUV39H2 gRNA sequences using Fugene HD (Promega). SUV39H1 gRNA sequence (ASON 2868, ASP 2985): 5'-caccgGTTCCTCTTAGAGATACCGA-3'. SUV39H2 gRNA sequence (ASON 2878, ASP 2990): 5'-caccgAAAGCTCTACAAGATGGCGG-3'. After 4--5 days, GFP-positive cells were single-cell sorted into 96-well plates using a Sony SH800 cell sorter. Clonal populations were expanded and screened by western blotting for SUV39H1. Mutations in SUV39H1 and SUV39H2 were confirmed by purifying genomic DNA, PCR amplifying the targeted locus, and analyzing the amplicons by high throughput sequencing on a MiSeq system (Illumina).

DLD-1 cell lines with point mutations in the endogenous SUV39H1 locus were generated by first making a SUV39H2 KO cell line (ASTC 269, described above), then performing further genome editing by co-transfecting pX458 (pSpCas9(BB)−2A-GFP) with a SUV39H1-targeting gRNA (ASP 2987; 5'-caccgGGATCTTCTTGTAATCGCAC-3') and a puc18 homology arm construct containing desired point mutations (R55A: ASP 3223, F43A: ASP 3222, or R55A/F43A: ASP 3543) with Fugene HD. After 4--5 days, GFP-positive cells were single-cell sorted into 96-well plates using a Sony SH800 cell sorter. Clonal populations were expanded and screened by western blotting for SUV39H1. Mutations in SUV39H1 were confirmed by purifying genomic DNA, PCR amplifying the targeted locus, and analyzing the amplicons by Sanger sequencing.

Immunofluorescence {#s4-3}
------------------

For mitotic spreads, cells were grown to about 70% confluency in T-25 or T-75 flasks, then mitotic cells were selected by shaking off less adherent cells. Released cells were pelleted, resuspended in 100 μL 75 mM KCl, then counted on a hemocytometer and diluted with more 75 mM KCl to 2 × 10^∧^5 cells/mL. 100 μL cells were spun onto no. 1.5 glass coverslips using a Shandon Cytospin 4 at 2000 rpm for 5 min. Coverslips were hydrated with KCM buffer (10 mM Tris-HCl pH 8.0, 120 mM KCl, 20 mM NaCl, 0.5 mM EDTA, 0.1% Triton X-100), then cells were permeabilized for 10 min with KCM buffer with 0.5% Triton X-100. Coverslips were blocked with KCM + 2% BSA for 30 min, then stained with specific antibodies diluted in KCM + 2% BSA, 30 min each. After staining, cells were washed with KCM buffer and fixed with 3.7% formaldehyde in KCM for 10 min. After fixation, cells were washed with PBS, stained with 10 μg/mL Hoescht for 10 min, washed with PBS + 0.1% Triton X-100, washed with PBS, then mounted onto microscope slides.

For staining interphase DLD-1 cells, cells were plated on glass coverslips, fixed and permeabilized with 1% formaldehyde, 0.5% Triton X-100, 1X PBS for 10 min, then re-permeabilized with 0.5% Triton X-100, 1X PBS for 10 min. Cells were blocked in antibody dilution buffer (AbDil: 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 2% BSA, 0.1% sodium azide) for 30 min, then stained with primary and secondary antibodies diluted in AbDil for 30 min each. Cells were then stained with 10 μg/mL Hoechst in Abdil for 10 min, washed with PBS + 0.2% Triton X-100, washed with PBS, then mounted onto slides and imaged.

We used the following antibodies for immunofluorescence: mouse anti-HEC1 (Abcam ab3613, 1:1000), rabbit anti-CENP-A-Alexa647 (Straight laboratory, 1:1000), rabbit anti-GFP-Alexa488 (Straight laboratory, 2 μg/mL), rabbit anti-HP1α (Straight laboratory, 2 μg/mL), rabbit anti-H3K9me3 (Abcam ab8898, 1:1000), human anti-centromere protein (CREST, Antibodies, inc., 1:100). All secondary antibodies were obtained from Invitrogen and diluted 1:1000. For experiments where SUV39H1-GFP localization was assessed, expression of WT or mutant versions of SUV39H1-GFP was induced in HeLa Flp-In T-REx cells with 1 μg/mL doxycycline for 6 hr before mitotic shake off. To visualize RNA by EU labeling, cells were incubated with 0.5 mM EU (synthesized as previously described \[[@bib41]\]) for 4--12 hr before mitotic shake off. In RNA polymerase inhibitor experiments, cells were incubated with 0.5 mM EU and 50 μg/mL α-amanitin (Santa Cruz Biotech.), 1 μM triptolide (Selleckchem), 50 ng/mL actinomycin D (Calbiochem), or 1 μM CX-5461 (Millipore) for 6 hr. Cells were processed and stained as above. After fixation, cells were washed with PBS, and EU-containing RNA was labeled using a Click-iT RNA Imaging kit (Invitrogen C10329), essentially according to the manufacturer's instructions. In RNase sensitivity experiments, 0.5 mg/mL RNase A (Sigma), III, or H was included in the 30 min block step before antibody staining (in KCM --EDTA + 5 mM MgCl~2~ in experiments with RNase H and RNase III). Plus inhibitor (+inhibitor) controls also containing 4 U/μL each of RNaseOUT (Invitrogen) and RNase inhibitor (Ambion AM2684).

Stacks of fixed spread mitotic chromosomes and interphase nuclei were acquired at 0.2 μm axial steps using a motorized stage mounted on an Olympus IX70 microscope, using a 100X, 1.4 NA PlanApo objective and a CoolSnap-HQ CCD camera (Photometrics) on a DeltaVision Spectris system (Applied Precision). Displayed images are maximum intensity projections of raw or deconvolved z-stacks.

Fluorescent signal at pericentric regions of mitotic chromosomes or at centromeres in interphase nuclei was quantified using custom software. Pericentromere finder ([@bib27]): centromeres were localized using HEC1 staining, and pericentric regions were defined by segmenting on DNA on Hoescht-stained chromosomes within a 10-pixel radius around centromeres. Parameters used were min-size = 4, max-intercentromere-dist = 17, marker-channel = 2 (HEC1 staining), and pericentromere-channel = 0 (DNA staining). Centromere finder ([@bib28]): centromeres were localized using CREST staining, and fluorescence of each channel was measured. Parameters used were min_size = 5, max_size = 60, marker_channel_index = 3 (CREST staining), decrease_speckle_background = false. Intensity measurements were performed on non-deconvolved maximum intensity projections of each z-series. GFP background signal was assessed by imaging spreads from cells that were not induced with doxycycline, and therefore were not expressing SUV39H1-GFP. Background in the HP1α channel was assessed by imaging spread cells not stained with HP1α primary antibody, and EU-RNA background was assessed with a no EU treatment control.

RNA FISH {#s4-4}
--------

Mitotic DLD-1 cells were selected by mitotic shake off, washed with PBS, resuspended in 75 mM KCl to 5.8 × 10^4^ cells/mL, then swelled at 37°C for 15 min. 500 μL cells were cytospun onto RNase AWAY treated slides (2000 rpm, 10 min). Cells were permeabilized in KCM buffer for 5 min, fixed in 4% PFA in PBS for 10 min, then blocked for 15 min (1X PBS, 0.5% Triton X-100, 1% BSA) and stained with specific antibodies (described above) in block. Cells were permeabilized again in CSK buffer/2 mM RVC(Ribonucleoside Vanadyl Complex)/0.5% Triton X-100, 10 min on ice, then fixed again in 4% PFA in PBS for 10 min. Slides were dehydrated with an ethanol series (70%, 80%, 95%, 100%, 2 min each on ice), then air-dried at 37°C. After precipitating and denaturing, probes were hybridized in hybridization mix (+RVC) at 37°C overnight in a humid chamber (pSD1-1 and ASP851 probes: 65% formamide; pβ4 and pTRS-47 probes: 50% formamide). Slides were then washed with 2X SSC/0.05% Tween/formamide (same formamide percentages used in hybridization mix), pH 7 at 37°C, 3 times 5 min each \-- then with 2X SSC/0.05% Tween, at 37°C, 3 times 5 min each -- then 1X SSC/0.05% Tween, at room temp, 10 min -- then 4X SSC/0.1% Tween, at room temp, 5 min. For biotin-16-dUTP labeled probes, after post-hybridization washes, slides were blocked in blocking buffer (PBS + 0.5% Triton X-100 + 1% BSA + 0.02% sodium azide) and biotin was detected with Alexa Fluor 488 streptavidin diluted in blocking buffer for 2 hr at room temperature. Slides were then washed with 4X SSC/0.1% Tween three times at room temp, 5 min each. All slides were stained with DAPI, coverslips were mounted, and images were acquired as described above. CSK buffer: 100 mM NaCl, 300 mM sucrose, 3 mM MgCl~2~, 10 mM PIPES pH 6.8. Probe hybridization mix: 50% formamide (65--68% for repetitive), 10% dextran sulfate, 2X SSC, 1% Tween-20. RNase-treated controls slides were incubated with Ambion RNase cocktail (7.5 μL/mL KCM buffer) at 37°C for 2 hr up to overnight before hybridization.

DNA FISH was performed as above, with the following differences: slides were fixed in 10% formalin for 10 min at room temp, permeabilized in KCM for 10 min, denatured in 70% formamide, 2X SSC, pH 7 at 70°C for 3 min, then hybridized overnight.

All probes were labeled by nick translation of plasmids either indirectly with Roche biotin-16-dUTP and subsequently detected with AlexaFluor 488 streptavidin or directly with AlexaFluor 488-dUTP. D1Z5-specific RNA FISH probes were generated from the pSD1-1 plasmid, which contains a single copy of the 1.9 kb D1Z5 higher order repeat (HOR). Probes recognizing chromosome 13 and chromosome 21 α-satellite arrays were generated using a template PCR amplified from human genomic DNA with the following primers: α-satellite I (ASON 614): 5'-CTTGCTAGCAATCTGCAAGTGG-3', and α-satellite II (ASON 615): 5'-CTTGTCGACTACAAAAAGAGTG-3'. β-satellite is detected with nick-translated plasmid pβ4, which recognizes β-satellite sequences on the acrocentric chromosomes (chromosomes 13, 14, 15, 21, and 22). Satellite III is detected with nick-translated plasmid pTRS-47, which recognizes Satellite III subfamily sequences on chromosomes 14 and 22. pSD1-1, pβ4, and pTRS-47 plasmids were a gift from the lab of Dr. Huntington Willard. 500 ng of 488 dUTP-labeled probes were precipitated with 0.5 uL salmon sperm DNA (10 mg/mL stock) and 2.5 volumes 100% EtOH for each 18 × 18 cm^2^ area for at least 4 hr at −80° C or overnight at −20° C. Before use, probes were pelleted at maximum speed in an Eppendorf microcentrifuge, washed with 70% ethanol, resuspended in 65% formamide hybridization mix, and denatured at 74°C for 10 min.

The 'RGB profile plot' ImageJ plugin was used for line scan analysis of RNA FISH images.

Protein expression {#s4-5}
------------------

All purified SUV39H1 proteins used in this study were expressed as N-terminal Maltose Binding Protein (MBP) fusions. pMAL-c2X (NEB) expression vectors, carrying sequences encoding truncated versions of human SUV39H1, were transformed into BL21 *E. coli* and grown in 2--6 L of 2X YT at 37°C to an OD of 0.6--0.8. Cells were induced with 0.3 mM IPTG for 4--6 hr at room temperature. Cells were harvested, frozen in liquid nitrogen and stored at −80°C.

Protein purification {#s4-6}
--------------------

Each liter of pelleted *E. coli* culture was resuspended in 20 mL of ice cold 4X lysis buffer (80 mM Tris-HCl pH 7.4, 0.8 M NaCl, 0.4% Triton X-100, 5 mM 2-mercaptoethanol, 1 mM PMSF, 1 mM benzamidine hydrochloride, 0.2 mg/ml lysozyme). Lysates were sonicated and centrifuged at 96,000Xg for 1 hr at 4°C. Supernatants were passed over 2--5 mL of either amylose resin (NEB) or glutathione agarose (Sigma Aldrich), followed by washing with approximately 10 column volumes of 4X lysis buffer, 30 column volumes of 1X lysis buffer (20 mM Tris-HCl pH 7.4, 0.2 M NaCl, 0.1% Triton X-100), and five column volumes of 1X lysis buffer without Triton X-100 at 4°C. Protein was eluted with approximately five col. volumes of 1X lysis buffer without Triton X-100 plus either 10 mM maltose or 5 mM glutathione. MBP fusions were dialyzed into 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 10% glycerol, 5 mM 2-mercaptoethanol. For alanine scanning point mutants, frozen pellets from 100 mL cultures were thawed and resuspended in 5 mL of 4X lysis buffer. Lysates were sonicated, divided into 5 × 1 mL aliquots and spun at approximately 20,000Xg for 20 min at 4°C. Supernatants were combined and incubated with 500 μL of amylose resin (NEB) for 30 min at 4°C. The amylose resin was washed 3 times with 1 mL of 4X lysis buffer, 3 times with 1 mL of 1X lysis buffer without Triton X-100, and 3 times with 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 10% glycerol, 5 mM 2-mercaptoethanol. Protein was eluted with 750 μL of 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 10% glycerol, 5 mM 2-mercaptoethanol, 10 mM maltose for 30 min at 4°C. Amylose resin was pelleted by spinning at 20,000Xg for 2 min, and supernatants were collected. To remove contaminating RNases, proteins were loaded onto a 1 or 5 mL HiTrap SP sepharose FF column (GE) using an AKTA FPLC. The flowthrough fraction was taken and concentrated using Amicon Ultra 30 kDa centrifugal filters (EMD Millipore). Protein concentrations were quantified by Bradford assay and A~280~ measurement using a NanoDrop 1000 spectrophotometer. The absence of co-purifying nucleic acids was monitored by ensuring the absorbance ratio at 260 nm/280 nm was less than 0.7.

Nucleic acid sequences used in EMSAs {#s4-7}
------------------------------------

RNA and DNA probes ≤50 bp were ordered from Integrated DNA Technologies.

Sense 19mer,

5'-AUAUGGGAACCACUGAUCC-3';

antisense 19mer,

5'-GGGAUCAGUGGUUCCCAUA-3';

sense MBP 1--50,

5'-ACCAAAAUCGAAGAAGGUAAACUGGUAAUCUGGAUUAACGGCGAUAAAGG-3';

antisense MBP 1--50,

5'-CCUUUAUCGCCGUUAAUCCAGAUUACCAGUUUACCUUCUUCGAUUUUGGU-3'.

To synthesize 180 bases of α-satellite or β-actin ssRNA, cDNAs were obtained from HeLa cell total RNA using the SuperScript III First-Strand Synthesis System (Life Technologies) according to the manufacturer's instructions, and the following primers:

α-satellite forward,

5'-CTTGCTAGCAATCTGCAAGTGG-3';

antisense β-actin,

5'-CGTAGATGGGCACAGTGTGG-3'.

cDNA was amplified into dsDNA using Phusion high-fidelity DNA polymerase (NEB) and the following primer pairs; α-satellite forward (sequence above) and

α-satellite reverse +T7,

5'- GTAATACGACTCACTATAGGGcttgtcgactacaaaaagagtg-3';

antisense β-actin (sequence above) and sense β-actin + T7,

5'- GTAATACGACTCACTATAGGGAGGCCCCCCTGAACCCCAAG-3'.

dsDNA was used for in vitro transcription as described below.

Radiolabeling of nucleic acids {#s4-8}
------------------------------

Nucleic acids were end-labeled using ATP γ-^32^P (Perkin Elmer) and polynucleotide kinase (NEB). Approximately 15 pmol of ATP γ-^32^P was added to 5--10 pmol of nucleic acid, polynucleotide kinase, and 10X reaction buffer, and incubated for 75 min at 37°C. The polynucleotide kinase was subsequently deactivated by incubating at 68°C for 20 min. Free ATP γ-^32^P was separated from labeled nucleic acids using Micro Bio-spin Columns with Bio-Gel P-6 (Bio Rad) according to the manufacturers protocol, and exchanged into 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 10% glycerol in DEPC H~2~O. Labeled nucleic acids were diluted into approximately 1.5 mLs of Tris-HCl pH 7.4, 50 mM NaCl, 10% glycerol in DEPC H~2~O to a final concentration of approximately 1--5 nM. MBP 1--50 nucleic acids were further purified by native gel electrophoresis (13.33% acrylamide 29:1, 0.5X TBE). Bands were identified using HyBlot CL Autoradiography Film (Denville Scientific), excised and eluted for 3 hr at 25°C into 1 mL of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 10% glycerol in DEPC H~2~O at a final concentration of ≤1 nM. α-satellite and β-actin ssRNAs were further purified by denaturing gel electrophoresis (10% urea, 10% acrylamide 29:1, 1X TBE). Bands were identified using HyBlot CL Autoradiography Film (Denville Scientific), excised and eluted for 3 hr at 25°C into 1 ml DEPC H~2~O with the addition of 160 units of RNase Inhibitor (Ambion, AM2684). RNA was concentrated using Amicon Ultra 30 kDa centrifugal filters and washed 3 times with 500 μL DEPC H~2~O. RNA was resuspended in 1 mL of 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 10% glycerol, made with DEPC-treated water at a final concentration approximately ≤1 nM.

In vitro transcription {#s4-9}
----------------------

RNA was transcribed from α-satellite and β-actin dsDNA (from cDNA described in previous section, nucleic acid sequences used in EMSAs) using the MEGAscript T7 Transcription Kit (Life Technologies) according to the manufacturers protocol, with the addition of 40 units of RNase Inhibitor (Ambion, AM2684). Transcribed RNA was loaded onto a 1% agarose gel to verify lengths, and RNA concentrations were measured using a NanoDrop 1000 spectrophotometer. Approximately 2 μg of RNA was desphosphorylated for 60 min at 37°C using Antarctic Phosphatase (NEB) with the addition of 40 units of RNase Inhibitor (Ambion, AM2684) in preparation for end-labeled using ATP γ-^32^P.

Electrophoretic mobility shift assays (EMSAs) {#s4-10}
---------------------------------------------

Purified proteins and nucleic acids were thawed at room temperature and kept on ice. Proteins were serially diluted into binding buffer (20 mM Tris-HCl pH 7.4, 50 mM NaCl, 10% glycerol in DEPC H~2~O) and kept on ice until mixed with RNA. Proteins were mixed with ^32^P-labeled nucleic acids and approximately 4 units RNase Inhibitor (Ambion, AM2684), and allowed to equilibrate to at room temperature for 10 min before loading onto a native gel (7.5--13.33% acrylamide 29:1, 0.5X TBE) buffered with 0.5X TBE. Gel electrophoresis was carried out for 1 hr at 25°C at 10 mAmps. Gels were exposed to phosphorimaging screens for approximately 1 hr before signal acquisition was performed using a Typhoon 9400 Variable Mode Imager (GE). Gels were quantified using FIJI software, and binding curves, dissociation constants, and standard error were plotted and calculated using Graphpad Prism software.

Alanine scanning mutagenesis {#s4-11}
----------------------------

Individual alanine point mutants were synthesized using PCR assembly of six overlapping DNA oligonucleotides (Integrated DNA Technologies) of approximately 60 bp, spanning a 5' AscI site, the SUV39H1 chromodomain (residues 42--106), and a 3' PacI site. Following PCR assembly, DNA was purified using Agencourt AMPure XP beads. 40 μL of each PCR product was mixed with 72 μL Ampure beads and incubated for 5 min at 25°C. Beads were collected using a 24-well magnetic stand for 5 min, and washed twice with 200 μL 70% ethanol. Beads were air-dried for 20 min at 25°C, and DNA was eluted with 40 μL of H~2~O for 5 min at 25°C. Recovered DNA was quantified using a NanoDrop 1000 spectrophotometer. Each point mutant was cloned into the AscI/PacI sites of the pMAL-c2X vector and verified by sequencing.

Filter binding assays {#s4-12}
---------------------

Purified proteins and nucleic acids were thawed at room temperature and kept on ice. Proteins were serially diluted into binding buffer (20 mM Tris-HCl pH 7.4, 50 mM NaCl, 10% glycerol in DEPC H~2~O) and kept on ice until mixed with RNA. Proteins were mixed with ^32^P-labeled sense 19mer RNA and approximately 4 units RNase Inhibitor (Ambion, AM2684), and allowed to equilibrate to at room temperature for 10 min. 4 μL of each binding reaction was dotted onto a nitrocellulose membrane. The membrane was washed several times with binding buffer without glycerol, and membranes were exposed to phosphorimaging screens and imaged using a Typhoon 9400 Variable Mode Imager (GE). Gels were quantified using FIJI software, and binding curves, dissociation constants, and standard error were plotted and calculated using Graphpad Prism.

In vitro peptide binding assays {#s4-13}
-------------------------------

SUV39H1 42--106 proteins were diluted to a final concentration of 12.5 μM in 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 10% glycerol. Histone H3 1--20 peptides (EpiCypher) were diluted to 40 μM in peptide binding buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.05% NP-40, 10 mg/mL BSA). 5 μL of SUV39H1 42--106 (1.25 μM final concentration) was mixed with 1 μL peptide (800 nM final concentration) and 44 μL peptide binding buffer and incubated for 45 min at 4°C. 20 μL of Dynabeads M-280 Strepavidin (Life Technologies) were washed 3 times with 1 mL of peptide binding buffer, added to the binding reaction and incubated for 45 min at 4°C. Beads were washed 4 times with 1 mL of peptide binding buffer and eluted with 100 μL of protein SDS sample buffer (10% SDS, 50% glycerol, 0.05% bromophenol blue, 0.2 M Tris-HCl pH 6.8, 40 mM EDTA pH 8, 20% 2-mercaptoethanol). 20 μL was loaded onto a 12.5% polyacrylamide SDS denaturing gel and transferred onto a PVDF membrane for western blotting with anti-MBP antibody. Bands were quantified using FIJI software and p-values for an unpaired t-test were calculated using Graphpad Prism software.

Structure comparison {#s4-14}
--------------------

The structures of the chromodomains of human HP1α bound to H3K9me3 ([@bib44]) (PDB ID:3FDT) and human SUV39H1 ([@bib85]) (PDB ID:3MTS) were aligned using the Matchmaker Tool in the Chimera Software Package ([@bib65]). Residue F43 of SUV39H1 is not shown in the comparison because it is not present in the crystal structure.

Histone methyltransferase activity assay {#s4-15}
----------------------------------------

150 μg/mL full-length SUV39H1 proteins were incubated with 70 μg/mL Xenopus H3/H4 tetramer ([@bib34]), 0.8 μCi/mL ^14^C-SAM (Perkin Elmer), ±124 μg/mL β-actin RNA (360 bp, cDNA amplified with ASON 2584/2582 and reverse transcribed), in activity buffer (10 mM HEPES pH 7.7, 100 mM KCl, 1 mM MgCl~2~, 1 mM CaCl~2~, 0.5 mM DTT) in a final volume of 20 μL. Reactions proceeded at 30°C for the indicated time, then samples were boiled in SDS-PAGE loading buffer for 5 min and saved at −20°C. Samples were run on a 20% SDS-PAGE gel; the gel was fixed, Coomassie stained, and dried; and methylation was detected with a phosphorimaging screen scanned on a Typhoon 9400 Variable Mode Imager (GE).

Western blotting {#s4-16}
----------------

Rabbit anti-MBP, anti-GFP, and anti-HP1α polyclonal antibodies were generated by Cocalico Biologicals and purified from rabbit serum. All primary antibodies were incubated for 1 hr (except for anti-SUV39H1 which was incubated overnight) at the following dilutions: rabbit anti-MBP (Straight lab, 0.2 μg/mL), rabbit anti-GFP (Straight lab, 1 μg/mL), rabbit anti-HP1α (Straight lab, 1 μg/mL), mouse anti-SUV39H1 (Millipore clone MG44, cat. \#05--615, 1:500), rabbit anti-H3K9me3 (AbCam ab8898, 1:1000), rabbit anti-histone H4 (AbCam ab7311, 1:2000), and mouse monoclonal anti-tubulin (clone DM1α, Sigma T6199, 0.5 μg/mL).

To western blot for endogenous SUV39H1 in DLD-1 cells, nuclear lysates were prepared to enrich for the SUV39H1 containing fraction. Cells were incubated in hypotonic buffer (10 mM Tris-HCl pH 8, 1.5 mM MgCl2, 10 mM KCl) for 10 min on ice, dounced 10 times with a Kontes glass dounce (B pestle), nuclei were pelleted at 5000xg for 10 min, then lysed in DLB ([@bib79]). If necessary, lysates were sonicated with a Branson Sonifier S-250A using a microtip until no longer viscous. To test the effect of RNase A on SUV39H1 protein levels, pelleted nuclei were incubated with 0.5 mg/mL RNase A, ±4 U/μL RNaseOUT, for 30 min before lysis.

RNA immunoprecipitation (RIP) assay {#s4-17}
-----------------------------------

All buffers listed here are described in [@bib79]. HeLa Flp-In T-REx cell lines expressing GFP, WT SUV39H1-GFP, or R55A SUV39H1-GFP were expanded to six 15 cm dishes each, and protein expression was induced with 1 μg/mL doxycycline for 6 hr. Cells were trypsinized, pelleted, and then resuspended in 30 mL PBS. To crosslink cells, formaldehyde was added to a final concentration of 0.1%, and cells were rotated at room temperature for 10 min. Crosslinking was stopped by adding 3 mL quenching buffer, then rotating cells for 5 min. Cells were pelleted and lysed in 3 mL denaturing lysis buffer (DLB) on ice for 10 min. Lysates were sonicated with a Branson Sonifier S-250A using a microtip (setting 4.5, 2 rounds of 10 pulses), diluted up to 8 mL with DLB, then cleared by spinning at 12,800 rpm then 33,000 rpm in a Type 70.1 Ti rotor for 10 min each at 4°C. Lysates were all diluted to 0.3 mg/mL, 20 mL each, and samples were saved for western blotting and analysis of total input RNA. Remaining lysate was added to 40 μL NHS-activated sepharose coupled to a llama anti-GFP nanobody ([@bib73]) and rotated at 4°C for 2 hr. Beads were collected by brief centrifugation, and supernatant sample was saved for western analysis. Beads were washed 2 × 10 mL with denaturing wash buffer (DWB), 2 × 10 mL with isotonic wash buffer (IsoWB), then resuspended in 100 μL of clear sample buffer (CSB). Crosslinks were reversed in both input lysate and IP samples by heating at 75°C for 40 min. 5 μL of each IP supernatant was saved for western blotting and silver staining, and the remaining supernatant and input lysates were mixed with 1 mL TriPure isolation reagent (Roche). RNA was purified using TriPure, then treated with 10 units of TURBO DNase (Life Technologies) at 37°C overnight according to the manufacturer's instructions. RNA was re-purified with TriPure, resuspended in 20 μL DEPC-treated water, then analyzed by RT-qPCR. Silver staining of immunoprecipitated material was performed essentially as described ([@bib17]).

RT-qPCR {#s4-18}
-------

RNA was reversed transcribed into cDNA using the SuperScript III First-Strand Synthesis System (Life Technologies 18080--051) per manufacturer's instructions, using the following RT primers: α-satellite I (ASON 614): 5'-CTTGCTAGCAATCTGCAAGTGG-3', β-actin rev (ASON 2430): 5'-ATGTCCACGTCACACTTCAT-3', and GAPDH rev: 5'-CCTGCTTCACCACCTTCTT-3'. Quantitative PCR (qPCR) was then performed with the same reverse primers plus the following forward primers: α-satellite II (ASON 615): 5'-CTTGTCGACTACAAAAAGAGTG-3', β-actin fwd (ASON 2392): 5'-AGAGCTACGAGCTGCCTGAC-3', and GAPDH fwd: 5'-AGATCATCAGCAATGCCTCC-3'. qPCR mix recipe: 1X Phusion HF buffer (NEB), 3% DMSO, 200 µM dNTPs, 1X ROX reference dye (Life Technologies), 1X SYBR green I (Invitrogen S-7563), Phusion polymerase, and 100 nM each primer. The following programs were used: α-satellite (98°C 30 s, then 40X cycles of 98°C 15 s, 60°C 15 s, 72°C 15 s), β-actin (98°C 30 s, then 40X cycles of 98°C 10 s, 72°C 30 s). qPCR was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems), and the number of cycles to reach the automatically set threshold (C~t~) were determined using Sequence Detection Systems software. For each primer set, standard curves of diluted cDNA were used to assess the exponential amplification (expAmp) of the amplicon. The signal in each experimental sample was determined by signal = expAmp^-Ct^. For all α-satellite measurements, '-RT' signal was subtracted from '+RT' signal, as the repetitive nature of α-satellite DNA leads to high background. α-satellite signal was then divided by the β-actin or GAPDH signal to get final α-satellite normalized signal. For IP enrichment values, the α-satellite normalized signal for the IP was then divided by the α-satellite normalized signal of the input lysate.

To test inhibition of transcription after adding RNA polymerase inhibitors, RT-qPCR was performed essentially as described above with the following primers:

pre-tRNA(tyr) fwd (ASON 1991): CCTTCGATAGCTCAGCTGGTAGAG

pre-tRNA(tyr) rev (ASON 1990): AAAAAACCGCACTTGTCTCCTTCG

GAPDH pre-mRNA fwd (ASON 4619): CATGCCTTCTTGCCTCTTGT

GAPDH pre-mRNA rev (ASON 4620): TGAGGTCAATGAAGGGGTCA

45S pre-rRNA fwd (ASON 1891): CCTGCTGTTCTCTCGCGCGTCCGAG

45S pre-rRNA rev (ASON 1892): AACGCCTGACACGCACGGCACGGAG

RNA-seq and analysis of repeat families {#s4-19}
---------------------------------------

For total RNA-seq analysis of control and SUV39 DKO HeLa and DLD-1 cells, total RNA was purified using TriPure, then treated with 10 units of TURBO DNase (Life Technologies) at 37°C for 30 min per the manufacturer's instructions. RNA was re-purified with TriPure, resuspended in DEPC-treated water, and quality checked by Bioanalyzer (Agilent). RNA was then analyzed either by RT-qPCR to measure α-satellite RNA levels as described above, or a cDNA library was generated for RNA-Seq analysis. For RNA-Seq, ribosomal RNAs were first depleted using a NEBnext rRNA depletion kit (New England Biolabs), RNA was purified using Agencourt Ampure XP beads (Beckman Coulter), then cDNAs were generated, amplified, and indexed with the ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicentre) per the manufacturer's instructions. Indexed libraries were quantified by Bioanalyzer and qPCR, pooled, and sequenced on a NextSeq 500 (Illumina).

For analysis of repetitive RNAs, raw fastq files were adapter trimmed and converted to fasta format. The fasta files were then split into smaller files of 1,000,000 sequences each. All smaller fasta files of each original fasta file were analyzed by RepeatMasker 4.0.3 using the human species database ([@bib8]). The RepeatMasker output file for each smaller fasta file was merged together to give the repeat content of the original fasta file. Repeat class and type was summarized using the buildSummary.pl script in the RepeatMasker utility script folder. The number of reads for each repeat in the RepeatMasker output file was normalized to the total number of repeats detected by RepeatMasker to obtain a frequency of detection for each repeat type. To calculate the fold enrichment for each repeat type, the frequency of each read in the SUV39 DKO cell line was divided by the frequency of the same read in the control cell line. A cutoff threshold for inclusion in the analysis was set at 300 reads per repeat type.

Analysis of non-repetitive RNA was performed by aligning reads (after PCR duplicate removal and adaptor trimming) to the UCSC hg38 build (downloaded Aug 14, 2015 and archived by Illumina iGenomes) using tophat2 (v 2.2.9). The aligned reads were annotated and quantified using Cufflinks (v 2.2.1).

Fluorescence recovery after photobleaching (FRAP) {#s4-20}
-------------------------------------------------

Flp-In HeLa cells containing WT or mutant SUV39H1-GFP were grown on glass-bottom chambered coverglass (LabTek) under standard conditions. SUV39H1-GFP expression was induced by adding 1 µg/mL doxycycline six hours before data collection. For drug treatment experiments, cells were treated with 1 μM CX-5461 (Millipore), 50 μg/mL α-amanitin (Santa Cruz Biotech), or 1 μM triptolide (Selleckchem) for 2 hr before image acquisition. Triptolide and α-amanitin experiments were done in cells induced with 50 ng/mL doxycycline for 24 hr. Immediately before the experiment, the media was exchanged to pH-indicator free media (DMEM, 10% FBS, constant doxycycline and drug concentration). Microscopy was performed with a Nikon Eclipse Ti at 100x magnification. Photobleaching was performed using an Andor Mosaic II patterned illumination system coupled to a 450 mW 405 nm laser. Photobleaching was performed using 100% power for one second using a circular spot with a diameter of \~3 µm. Images of the recovery were collected, and intensity profiles of the bleaching area and of the whole nucleus were calculated using ImageJ 2.0. Intensity profiles were normalized using the following formula:$$I = \frac{ROI_{(t)}}{ROI_{(0)}} \bullet \frac{total_{(t)}}{total_{(0)}}$$$$I_{norm} = \frac{I_{(t)} - I_{(bleach)}}{I_{(0)} - I_{(bleach)}}$$

Where ROI and total are the intensities of the photobleaching area and whole nucleus, respectively, at either time zero or at time *t*. The intensity at time zero is *I~(0)~* (i.e., before bleaching), *I~(bleach)~* is the intensity immediately after bleaching, and *I~(t)~* is the intensity at subsequent time intervals. The normalized intensity traces were then analyzed for each cell using the following single-exponential function:$$Y = Y_{max}~ \bullet \left( {1 - e^{{(\frac{- ln2}{t_{1/2}})}{({x - x_{0}})}}} \right)$$

where Y~max~ is the plateau of the recovery curve and t~1/2~ is the halftime for recovery, in seconds. The amplitude of the plateau is equivalent to the fraction of mobile protein.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"RNA-dependent stabilization of SUV39H1 at constitutive heterochromatin\" for consideration by *eLife*. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jessica Tyler as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This study explores the role of RNA in localization of the human SUV39H1 to chromatin. The authors perform a careful series of experiments showing that the stable association of a moderately overexpressed SUV39H1-EGFP protein with heterochromatic foci is RNase-sensitive. The authors further show that major satellite repeats are transcribed and give rise to RNAs that remain associated with mitotic chromosomes and are present in SUV39H1 immunoprecipitates. Using purified SUV39H1, the authors demonstrate that the enzyme binds to single stranded RNA of any sequence and identify specific mutations in the chromo domain of SUV39H1 that disrupt RNA binding without affecting its interaction with H3K9me3 peptides.

Finally, the authors demonstrate that the RNA binding mutations affect the stable binding of SUV39H1 to chromatin in vivo. Importantly, when the chromo domain RNA binding defective mutants are introduced into knockout cells, their weak association with centromeric heterochromatin is not further reduced by RNase treatment, providing strong support for the idea that specific interactions between the SUV39H1 chromo domain and RNA stabilize its association with heterochromatin. The experiments in the paper are straightforward and support the main conclusion of the paper. The model that the authors present, suggesting that non-specific RNA binding works alongside H3K9me3 to stabilize the association of SUV39h1 with chromatin, is reasonable and potentially important.

However, what is lacking in the study is any demonstration that the RNA binding activity described by authors contributes to the silencing function of SUV39H1 in vivo. This seems like a major shortcoming that needs to be addressed prior to publication.

Essential revisions:

1\) A demonstration of functional importance of the RNA binding needs to be performed. This should be tested by introducing wildtype versus RNA-binding mutant SUV39H1 into their SUV39H1/H2 DKO cells and seeing what happens to H3K9me levels and what happens to Silencing of major satellite repeats and other transposons?

2\) The authors make the intriguing observation that transcription of α satellite RNA is not eliminated by inhibition of RNA pol II, but is eliminated by the inhibition of both RNA pol I and pol II (actinomycine D treatment). It would be very surprising if this were in fact the case. Does pol I localize to α repeats (by ChIP)? I think that the more likely explanation might be that their α-amanitin treatment is not inhibiting pol II completely. You need to show data that more convincingly clarify whether only PolII transcription is occurring, or better evidence for Pol I transcription at the α satellites.

3\) [Figure 4A and C](#fig4){ref-type="fig"} -- you need to state the binding affinity of R55A & R84A mutants for nucleic acid substrates used in [Figure 3C-F](#fig3){ref-type="fig"} to determine whether the decrease in binding is specific to RNA substrates. Without these data the assertion that R55A and R84A mutants are defective for binding to RNA only is untested in vitro, and would need to be removed from the text.

4\) Comparing [Figure 4E, F](#fig4){ref-type="fig"} and [5C](#fig5){ref-type="fig"}: Is the decrease in R55A\'s ability to bind to α-satellite RNA due to a decrease in H3K9me binding or interaction with RNA? The in vitro binding experiments (4E, F) reveal a decrease in H3K9me binding for R55A compared to the wild-type protein. This can contribute to the in vivo decrease in RIP signal in [Figure 5C](#fig5){ref-type="fig"}. This should be ruled out experimentally (see below).

5\) A prediction of the proposed model is that loss of CD-mediated nucleic acid and H3K9me binding together should reduce SUV39H1 interaction with α-satellite RNAs more than either mutation alone. This can be done by creating a protein carrying a nucleic acid-binding mutation (R55A/R84A) with an H3K9me-binding mutation (W64/F43) (or a SET domain mutation in a Suv39H1/H2 mutant cell line). RIP experiments with these mutants will permit the authors to test this prediction directly. Either these experiments should be done or the model toned down.

6\) [Figure 2](#fig2){ref-type="fig"} and 6. Please show data to demonstrate that RNase A treatment of cells does not cause a decrease in SUV39H1 protein levels.

Other revisions:

1\) [Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} -- why only 4 out of the 8 cell lines tested show α-satellite pericentric RNA localization in mitosis? It will be good to see RNA-FISH data for HeLa cells as well.

2\) For [Figure 3](#fig3){ref-type="fig"} -- what is the affinity of NTE (1-42 aa\'s), for different nucleotide substrates? It will be good control to understand if NTE, by itself, has any nucleotide binding capacity.

3)Subsection "RNA associates with the pericentric regions of human mitotic chromosomes", last paragraph: Are there other genomic regions where the RNA is associated with mitotic chromosomes in cis? If yes, then what are those euchromatic/heterochromatic regions?

4\) [Figure 6A and C](#fig6){ref-type="fig"} -- is the methylation efficiency of R55A and R84A mutants comparable to that of wild type protein? This will also impact results presented in [Figure 6---figure supplement 1D and E](#fig6s1){ref-type="fig"}.

5\) Subsection "A model for the RNA-dependent stabilization of SUV39H1 on chromatin", first paragraph. The discussion of the pombe HP1/Swi6 and its requirement for Clr4-dependent H3K9me is incorrect. Even though this was shown in the referenced paper, subsequent work using the complete deletion of swi6 (instead of a this special swi6 mutant) have shown that loss of Swi6 has little impact on Clr4-dependent H3K9me (Sadaie et al. 2004 EMBO; Motamedi et al. 2008 Mol Cell).

6\) [Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}. Please show error bars for wt and calculate p values for these data.

7\) Subsection "SUV39H1 depends on direct RNA binding for its stable association with heterochromatin", first paragraph. Please keep mobile/immobile percentages consistent between wt and mutant proteins. For example, convert 42% immobile fraction to 58% mobile considering the mobile fraction of mutants is indicated.
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Author response

*Essential revisions:*

*1) A demonstration of functional importance of the RNA binding needs to be performed. This should be tested by introducing wildtype versus RNA-binding mutant SUV39H1 into their SUV39H1/H2 DKO cells and seeing what happens to H3K9me levels and what happens to Silencing of major satellite repeats and other transposons?*

We agree with this suggestion, and have now assessed the functions of the SUV39H1 nucliec acid binding mutants on the levels of H3K9me3 and on transcription of α-satellite sequences. To do this, we used CRISPR/Cas9 to make individual nucleic acid binding and H3K9me3 binding mutations in the endogenous SUV39H1 gene. We performed this gene editing in SUV39H2 knockout cells so that the activities of SUV39H2 did not obscure the analysis of mutant phenotypes. The results, shown in the new [Figure 8](#fig8){ref-type="fig"}, demonstrate that both nucleic acid binding and H3K9me3 binding by SUV39H1 contribute to α-satellite repression, and that ablating both interactions is largely equivalent to removing SUV39H1 altogether ([Figure 2---figure supplement 1J](#fig2s1){ref-type="fig"}). The loss of repression of α-satellite sequences is accompanied by measurable decreases in H3K9me3 methylation. Interestingly, the R55A/F43A double mutant displays no additional defect in H3K9me3 compared to F43A alone, even though it shows a significant increase in α-satellite RNA levels -- suggesting RNA binding of SUV39H1 may contribute to H3K9 methylation-independent roles for SUV39H1 in transcriptional repression. We believe this new data convincingly shows the functional importance of RNA binding by SUV39H1 and its importance in maintaining silencing of constitutive heterochromatin, and significantly strengthens the manuscript.

*2) The authors make the intriguing observation that transcription of α satellite RNA is not eliminated by inhibition of RNA pol II, but is eliminated by the inhibition of both RNA pol I and pol II (actinomycine D treatment). It would be very surprising if this were in fact the case. Does pol I localize to α repeats (by ChIP)? I think that the more likely explanation might be that their α-amanitin treatment is not inhibiting pol II completely. You need to show data that more convincingly clarify whether only PolII transcription is occurring, or better evidence for Pol I transcription at the α satellites.*

We agree that incomplete Pol II inhibition could explain the EU-RNA signal on chromosomes after α-amanitin treatment. Because we were unable to find a Pol I antibody suitable for ChIP, we addressed this issue by performing a new set of experiments using a more diverse panel of RNA polymerase inhibitors -- including triptolide, that exhibits much faster Pol II inhibition kinetics than α-amanitin (Bensaude, 2011) -- and by providing a more quantitative assessment of EU-RNA levels and RNA polymerase inhibition specificity (new [Figure 1---figure supplement 2A, B](#fig1s2){ref-type="fig"}). We find that both Pol II inhibitors (α-amanitin and triptolide) decrease EU-RNA levels by about 50%; however, our RT-qPCR analysis shows that EU-RNA levels largely correlate with Pol I inhibition, and although actinomycin D and CX-5461 show no inhibition of Pol II, they reduce EU-RNA down to background levels. This strongly indicates that the EU-RNA signal on mitotic chromosomes is predominantly transcribed by Pol I. The EU-RNA signal we observe likely includes other RNAs in addition to α- satellite. To examine α-satellite transcripts directly, we measured their levels by RT-qPCR and observed that none of our polymerase inhibition conditions led to a decrease in total α-satellite (although triptolide treatment resulted in a substantial α-satellite RNA increase) ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). This suggests that the α-satellite transcribed during our 6 hr treatment is likely a small subset of total α-satellite.

*3) [Figure 4A and C](#fig4){ref-type="fig"} -- you need to state the binding affinity of R55A & R84A mutants for nucleic acid substrates used in [Figure 3C-F](#fig3){ref-type="fig"} to determine whether the decrease in binding is specific to RNA substrates. Without these data the assertion that R55A and R84A mutants are defective for binding to RNA only is untested in vitro, and would need to be removed from the text.*

We agree that the R55A and R84A mutations likely disrupt binding to all nucleic acid substrates, including RNA and DNA. Therefore, we have changed our language in the manuscript to refer to these as nucleic acid binding mutants. One important note is that the treatment of mitotic chromosomes with RNase A, or treatment of interphase cells with RNA polymerase inhibitors, recapitulates defects of the nucleic acid binding mutants in these assays, indicating that the relevant binding substrate for SUV39H1 localization on chromosomes is likely RNA. Thus, in cases where we can ascribe the primary defect we observe in the mutants to RNA binding, we have maintained this phrase.

*4) Comparing [Figure 4E, F](#fig4){ref-type="fig"} and [5C](#fig5){ref-type="fig"}: Is the decrease in R55A\'s ability to bind to α-satellite RNA due to a decrease in H3K9me binding or interaction with RNA? The in vitro binding experiments (4E, F) reveal a decrease in H3K9me binding for R55A compared to the wild-type protein. This can contribute to the in vivo decrease in RIP signal in [Figure 5C](#fig5){ref-type="fig"}. This should be ruled out experimentally (see below).*

We acknowledge that the R55A mutation appears to cause a slight but insignificant decrease in SUV39H1 binding to H3K9me3. However, if the R55A mutation were really disrupting H3K9me3 binding, we would expect this to have a measurable effect on SUV39H1 localization. This is clearly not the case, as the localization defects of the R55A mutant -- observed by IF on mitotic chromosomes and by FRAP in interphase cells -- quantitatively matches the localization defects of R84A ([Figure 6](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"}), which exhibits no measurable defect in H3K9me3 binding ([Figure 4E, 4F](#fig4){ref-type="fig"}). Therefore, we can be confident that the RIP difference we observe is due to R55A's effects on nucleic acid binding, not on H3K9me3 binding (see also the response to point 5).

*5) A prediction of the proposed model is that loss of CD-mediated nucleic acid and H3K9me binding together should reduce SUV39H1 interaction with α-satellite RNAs more than either mutation alone. This can be done by creating a protein carrying a nucleic acid-binding mutation (R55A/R84A) with an H3K9me-binding mutation (W64/F43) (or a SET domain mutation in a Suv39H1/H2 mutant cell line). RIP experiments with these mutants will permit the authors to test this prediction directly. Either these experiments should be done or the model toned down.*

We agree that a prediction of our model is that breaking nucleic acid binding and H3K9me3 binding together should have a larger effect on SUV39H1 function than breaking either of these interactions in isolation. To test this, we have performed new experiments (new [Figure 8](#fig8){ref-type="fig"}) that demonstrate that a double mutant of SUV39H1 that disrupts both nucleic acid binding and H3K9me binding (R55A/F43A) causes more substantial derepression of α-satellite transcription than either individual mutant alone ([Figure 8F](#fig8){ref-type="fig"}). This experiment also addresses the above concern (point 4) -- that effects of the R55A mutant may be due to a slight decrease in H3K9me3 recognition ([Figure 4E, F](#fig4){ref-type="fig"}) -- in that an R55A mutation would not add an additional defect on top of that contributed by F43A if R55A were solely acting through disrupting H3K9me3 binding.

*6) [Figure 2](#fig2){ref-type="fig"} and 6. Please show data to demonstrate that RNase A treatment of cells does not cause a decrease in SUV39H1 protein levels.*

We have included a new supplemental figure ([Figure 2---figure supplement 1M](#fig2s1){ref-type="fig"}) showing that RNase treatment does not decrease SUV39H1 protein levels.

Other revisions:

*1) [Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} -- why only 4 out of the 8 cell lines tested show α-satellite pericentric RNA localization in mitosis? It will be good to see RNA-FISH data for HeLa cells as well.*

We have now included data showing α-satellite RNA FISH signal on HeLa mitotic chromosomes (new [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). Potential explanations for why we do not detect pericentric EU-RNA in all cells are: 1) RNA FISH is a more sensitive assay than EU-RNA labeling, EU is incorporated in only a subset of uridine positions and it only labels RNA transcribed during our incubation period, 2) there may be variation from cell line to cell line how much RNA is bound to chromosomes during mitosis. Because we can detect pericentric α- satellite RNA by RNA-FISH in both HeLas and DLD-1s, but only detect pericentric EU-RNA in HeLas, we conclude that the RNA FISH is the more reliable and sensitive assay.

*2) For [Figure 3](#fig3){ref-type="fig"} -- what is the affinity of NTE (1-42 aa\'s), for different nucleotide substrates? It will be good control to understand if NTE, by itself, has any nucleotide binding capacity.*

We agree this in an important consideration, and have purified MBP-SUV39H1 1-41 and measured its binding to the 19mer ssRNA (updated [Figure 3C](#fig3){ref-type="fig"}). We found that 1-41 exhibits greatly reduced RNA binding affinity (51 μM) compared to either of the truncations, including the chromodomain (1-106: 0.15 μM, 42-106: 2.3 μM). However, it is interesting that the NTE is making an additional contribution to nucleic acid binding, and we plan to explore this effect further in the future.

*3)Subsection "RNA associates with the pericentric regions of human mitotic chromosomes", last paragraph: Are there other genomic regions where the RNA is associated with mitotic chromosomes in cis? If yes, then what are those euchromatic/heterochromatic regions?*

We are also very interested in the RNAs bound to mitotic chromosomes, and we hope to further explore the identities and functions of these RNA in the future. We have begun preliminary experiments purifying mitotic chromosomes from human cells in the hopes of analyzing bound RNAs by RNA-seq. In addition, our lab has developed a new technique, ChAR-seq, to map chromatin-associated RNAs genome-wide (Bell et al., 2017) (<http://biorxiv.org/content/early/2017/03/20/118786>), and we plan to apply this technique to mitotic cell populations. However, we feel that a comprehensive characterization of other genomic regions that might have cis-associated noncoding RNAs is outside the scope of this manuscript. We plan to explore this in a future study using the new methods we are currently developing.

*4) [Figure 6A and C](#fig6){ref-type="fig"} -- is the methylation efficiency of R55A and R84A mutants comparable to that of wild type protein? This will also impact results presented in [Figure 6---figure supplement 1D and E](#fig6s1){ref-type="fig"}.*

We have included a new supplemental figure comparing the ability of SUV39H1 mutants to methylate histone H3/H4 tetramer in vitro ([Figure 6---figure supplement 1F](#fig6s1){ref-type="fig"}). The data show comparable methyltransferase activity between WT and mutants; however, our purified full-length SUV39H1 contains degradation products that make us wary of making quantitative comparisons. As observed in previous studies with other histone methyltransferases, we see that the addition of RNA to our reaction inhibits SUV39H1 methyltransferase activity (Cifuentes-Rojas et al., 2014; Kaneko et al., 2014). However, we see that this inhibition occurs with our nucleic acid binding mutants as well, suggesting that this RNA-dependent inhibition of methyltransferase activity is largely non-specific.

*5) Subsection "A model for the RNA-dependent stabilization of SUV39H1 on chromatin", first paragraph. The discussion of the pombe HP1/Swi6 and its requirement for Clr4-dependent H3K9me is incorrect. Even though this was shown in the referenced paper, subsequent work using the complete deletion of swi6 (instead of a this special swi6 mutant) have shown that loss of Swi6 has little impact on Clr4-dependent H3K9me (Sadaie et al. 2004 EMBO; Motamedi et al. 2008 Mol Cell).*

We thank the reviewers for alerting us to this important point. We have now corrected this sentence to more accurately describe the data in the literature.

6\) [Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}. Please show error bars for wt and calculate p values for these data.

We have now included error bars for the SUV39H1 WT measurement and calculate p values to describe HP1α localization defects in SUV39H1 mutants compared to WT.

*7) Subsection "SUV39H1 depends on direct RNA binding for its stable association with heterochromatin", first paragraph. Please keep mobile/immobile percentages consistent between wt and mutant proteins. For example, convert 42% immobile fraction to 58% mobile considering the mobile fraction of mutants is indicated.*

We have now changed all FRAP descriptions in the text to consistently refer to the mobile fraction.

[^1]: These authors contributed equally to this work.
